<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue journalpublishing.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Vis</journal-id><journal-id journal-id-type="publisher-id">MV</journal-id><journal-title-group><journal-title>Molecular Vision</journal-title></journal-title-group><issn pub-type="epub">1090-0535</issn><publisher><publisher-name>Molecular Vision</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17615537</article-id><article-id pub-id-type="publisher-id">a94</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Role of <italic>MYOC</italic> and <italic>OPTN</italic> sequence variations in Spanish patients with Primary Open-Angle Glaucoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>L&#x000f3;pez-Mart&#x000ed;nez</surname><given-names>Francisco</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>L&#x000f3;pez-Garrido</surname><given-names>Mar&#x000ed;a-Pilar</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>S&#x000e1;nchez-S&#x000e1;nchez</surname><given-names>Francisco</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Campos-Mollo</surname><given-names>Ezequiel</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Coca-Prados</surname><given-names>Miguel</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Escribano</surname><given-names>Julio</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><aff id="aff1"><label>1</label>Servicio de Oftalmolog&#x000ed;a, Complejo Hospitalario Universitario de Albacete (Hospital Perpetuo Socorro), Albacete, Spain</aff><aff id="aff2"><label>2</label>&#x000c1;rea de G&#x000e9;netica, Facultad de Medicina/Centro Regional de Investigaciones Biom&#x000e9;dicas (CRIB), Albacete, Spain</aff><aff id="aff3"><label>3</label>Servicio de Oftalmolog&#x000ed;a, Hospital Virgen de los Lirios, Alicante, Spain</aff><aff id="aff4"><label>4</label>Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, CT</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to: Julio Escribano, &#x000c1;rea de G&#x000e9;netica, Facultad de Medicina, Avda. de Almansa 14, 02006-Albacete, Spain; Phone: +34 967 599200, ext.: 2928; FAX: +34 902 204130; email: <email xlink:href="julio.escribano@uclm.es">julio.escribano@uclm.es</email></corresp></author-notes><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>14</day><month>6</month><year>2007</year></pub-date><volume>13</volume><fpage>862</fpage><lpage>872</lpage><history><date date-type="received"><day>26</day><month>3</month><year>2007</year></date><date date-type="accepted"><day>12</day><month>6</month><year>2007</year></date></history><permissions><copyright-year>2007</copyright-year><copyright-holder>Molecular Vision</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Purpose</title><p>To retrospectively investigate the contribution of <italic>myocilin</italic> (<italic>MYOC</italic>) and <italic>optineurin</italic> (<italic>OPTN</italic>) sequence variations to adult-onset ocular hypertension (OHT) and primary open-angle glaucoma (POAG) in Spanish patients.</p></sec><sec><title>Methods</title><p>The promoter region and the three exons of <italic>MYOC</italic> were analyzed by direct PCR DNA sequencing in 40 OHT and 110 POAG unrelated patients. We used 98 subjects in whom OHT or glaucoma had been ruled out as controls. We also screened the complete coding region of the <italic>OPTN</italic> gene (exons 4-16) in all subjects by single-stranded conformational polymorphisms (SSCPs).</p></sec><sec><title>Results</title><p>We identified six common single nucleotide polymorphisms (SNPs) in the promoter region of <italic>MYOC</italic> (-1000C&#x0003e;G, -387C&#x0003e;T, -306G&#x0003e;A, -224T&#x0003e;C, -126T&#x0003e;C and -83G&#x0003e;A) and a polymorphic GT microsatellite (-339(GT)11-19). In addition, we detected four novel, rare DNA polymorphisms. None of these DNA sequence variations were associated with either OHT or POAG. We also found three (2.7%) POAG patients with <italic>MYOC</italic> pathogenic mutations. Two of these pathogenic mutations (Gln368Stop and Ala445Val) were previously described whereas the third (Tyr479His) was novel. Transient expression of the novel mutation in 293T cells supported its pathogenicity. Only two <italic>OPTN</italic> polymorphisms, which are not associated with the disease, were detected.</p></sec><sec><title>Conclusions</title><p>Overall, our data show that in Spain a minority of adult-onset high-pressure POAG patients carry heterozygous disease-causing mutations in the <italic>MYOC</italic> gene and that <italic>OPTN</italic> is not involved in either OHT or POAG.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>GalleyStatus</meta-name><meta-value>Export to XML</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Glaucoma is a complex and genetically heterogeneous disease characterized by the progressive apoptotic death of retinal ganglion cells. This process leads to the excavation of the optic nerve head and to progressive and irreversible visual field loss [<xref ref-type="bibr" rid="r1">1</xref>,<xref ref-type="bibr" rid="r2">2</xref>]. Glaucoma is the second leading cause of blindness with prevalence of 0.15% in the total population and of approximately 2-4% among the population over the age of 40. Primary open-angle glaucoma (POAG) is the most common form of glaucoma, that manifests as an insidious and chronic condition characterized by a gonioscopically open angle. Although most people will not develop glaucomatous damage despite having an intraocular pressure (IOP) well above 21 mmHg, elevated IOP (&#x0003e;21 mmHg), originated by an increase in aqueous outflow resistance, is the most important risk factor in glaucoma [<xref ref-type="bibr" rid="r3">3</xref>]. It is speculated that elevated IOP could compress the optic nerve at the lamina cribosa. Depending on individual susceptibility factors, elevated IOP might damage ganglion cell axons and local glial cells as well as impair the capillary blood supply to the region. These events could progressively lead to the apoptotic death of ganglion cells [<xref ref-type="bibr" rid="r4">4</xref>]. Other risk factors include age, gender, myopia, and vascular and genetic factors. It has also been reported that changes in expression of genes such as p21(WAF1/CIP1) and 14-3-3 sigma may indicate an increased risk for glaucoma [<xref ref-type="bibr" rid="r5">5</xref>].</p><p>Genetically, POAG shows a complex pattern of inheritance with sporadic manifestations in most patients. The <italic>myocilin</italic> (<italic>MYOC</italic>) gene is mutated in 3-5% of sporadic patients in populations around the world [<xref ref-type="bibr" rid="r6">6</xref>-<xref ref-type="bibr" rid="r10">10</xref>]. This gene is composed of three exons and is ubiquitously expressed in many human tissues including the iris, ciliary body, and trabecular meshwork (TM) [<xref ref-type="bibr" rid="r11">11</xref>-<xref ref-type="bibr" rid="r13">13</xref>]. The majority of <italic>MYOC</italic> disease-causing mutations map to the olfactomedin-like domain of the protein, which is encoded by exon 3 [<xref ref-type="bibr" rid="r12">12</xref>]. In addition, heterozygous mutations in cytochrome P450 1B1 <italic>CYP1B1</italic>, a gene involved in primary congenital glaucoma, have been identified in 4-9% of affected POAG subjects from France [<xref ref-type="bibr" rid="r14">14</xref>,<xref ref-type="bibr" rid="r15">15</xref>], India [<xref ref-type="bibr" rid="r16">16</xref>], and Spain [<xref ref-type="bibr" rid="r17">17</xref>].</p><p>The <italic>optineurin</italic> (<italic>OPTN</italic>) gene consists of sixteen exons and the first three are noncoding. The <italic>OPTN</italic> gene is expressed in ocular tissues such as retina, TM, and nonpigmented ciliary epithelium [<xref ref-type="bibr" rid="r18">18</xref>]. Mutations in this gene predominately result in normal tension glaucoma [<xref ref-type="bibr" rid="r18">18</xref>], a subtype of glaucoma featured by normal IOP, but its role in high-pressure POAG is still controversial.</p><p>We report the first complete mutational analysis of the promoter and coding regions of <italic>MYOC</italic> and the coding region of the <italic>OPTN</italic> gene in Spanish patients diagnosed with adult-onset POAG. We found in this population, disease-causing mutations in the olfactomedin-like domain, encoded by the third exon of <italic>MYOC</italic>, are present in 2.7% of sporadic POAG cases. Our data also enable us to rule out a role of <italic>OPTN</italic> sequence variations in the development of POAG in Spanish patients.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Subjects</title><p>One hundred and ten unrelated native Spanish patients diagnosed with POAG and forty diagnosed with OHT, were studied retrospectively for <italic>MYOC</italic> and <italic>OPTN</italic> mutations. The control group was composed of 98 individuals in whom glaucoma was ruled out. All the individuals were recruited in the Department of Ophthalmology, University Hospital of Albacete, Spain ("Servicio de Oftalmolog&#x000ed;a, Complejo Hospitalario Universitario de Albacete").</p><p>The following conditions were required to diagnose POAG: exclusion of secondary causes (e.g., trauma, uveitis, steroid-induced or neovascular glaucoma); open anterior chamber angle (grade III-IV gonioscopy); IOP higher than 21 mmHg; characteristic optic disc changes; and an alteration of the visual field, tested by automated perimetry (with Humphrey's perimeter). The global indices such as mean deviation (MD) and pattern standard deviation (PSD) of the baseline visual fields were analyzed for all cases. All study subjects underwent a complete ocular examination. The study protocol was approved by the Ethics Committee for Human Research of the University Hospital of Albacete and followed the tenets of the Declaration of Helsinki. Informed consents were obtained from all the study subjects.</p><p>Patients were classified as having early (MD better than -6 dB), moderate (MD between -6 and -12 dB), or severe (MD worse than -12 dB) visual field alteration according to the classification by Hodapp et al. [<xref ref-type="bibr" rid="r19">19</xref>]. Medical treatment primarily included topical beta-blockers and prostaglandin analogues.</p></sec><sec><title>Sequence variation screening</title><p>Genomic DNA was extracted from the peripheral leukocytes of all studied subjects with the Perfect gDNA Blood Mini kit (Eppendorf, Madrid, Spain) according to the manufacturer's protocol. The promoter (nucleotides -1 to -1117) and the three exons of <italic>MYOC</italic> were amplified using primers designed to allow analysis of splicing consensus sequences (<xref ref-type="table" rid="t1">Table 1</xref>). PCRs were performed in a 50 &#x003bc;l volume containing 50-100 ng of genomic DNA, 10 pmol of forward and reverse primers, 2 mM MgCl<sub>2</sub> for exons 1 and 3, 0.5 mM MgCl<sub>2</sub> for exon 2, 100 &#x003bc;M of each dNTP, and 1 U of Taq DNA polymerase (Biotools, B&#x00026;M Labs, Madrid, Spain). Thermocycling included an initial denaturation step at 94 &#x000b0;C for four min followed by 35 cycles of denaturation, annealing, and extension (<xref ref-type="table" rid="t1">Table 1</xref>). A final cycle was performed at 72 &#x000b0;C for seven min. Terminator cycle sequencing was carried out using the BigDye&#x000ae; (v3.1) kit (Applied Biosystems, Foster City, CA). The products of sequencing reactions were analysed in an automated capillary DNA sequencer (ABI Prism 3100-Avant genetic analyzer; Applied Biosystems).</p><table-wrap id="t1" position="float"><label>Table 1</label><caption><title>Oligonucleotide primers used for amplification of the <italic>myocilin</italic> gene.</title></caption><table frame="hsides" rules="groups"><col width="62" span="1"/><col width="248" span="1"/><col width="72" span="1"/><col width="62" span="1"/><col width="65" span="1"/><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Region</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Primer sequence (5'-3')</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Annealing temperature and time (&#x000b0;C/s)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Extension time (s)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Amplicon length (bp)</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Promoter<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">F: TCCAGAAAGCCTGTGAATTTGA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">R: AGGCAGGCCAGAAGCAGC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">61.5/20<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1117<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon I<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">F: CTCACCAAGCCTCTGCAATG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">R: TGAACTCAGAGTCCCCCCAC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">62/20<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">15<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">654<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon II<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">F: ACATAGTCAATCCTTGGGCC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">R: CATGAATAAAGACCATGTGG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">55/20<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">239<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exon III<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">F: TCTGTGTTTGGAAAGATTATGG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">R: CCTGAGCATCTCCTTCTGCC</td><td valign="top" align="left" rowspan="1" colspan="1">59/30</td><td valign="top" align="left" rowspan="1" colspan="1">40</td><td valign="top" align="left" rowspan="1" colspan="1">890</td></tr></tbody></table><table-wrap-foot><p>Annealing temperature and time, extension time for each primer pair and the predicted length for each of the PCR DNA products in base pairs (bp) are listed. In the Primer sequence column, F indicates forward and R indicates reverse.</p></table-wrap-foot></table-wrap></sec><sec><title>Single stranded conformational polymorphism analysis</title><p>Mutations in the 13 coding exons (4-16) of the <italic>OPTN</italic> gene were screened by PCR-SSCP. Each exon was amplified by PCR in 50 &#x003bc;l reaction volumes using the primers, annealing temperatures, and times detailed in <xref ref-type="table" rid="t2">Table 2</xref>. Primers were also designed to allow analysis of splicing consensus sequences. Each reaction contained 2.0 mM MgCl<sub>2</sub>, 10 pmol of forward and reverse primers, 100-200 &#x003bc;M dNTPs, 0.5 U Taq Polymerase (Biotools), and 50-100 ng of genomic DNA. Reactions were denatured at 94 &#x000b0;C for four min followed by 35 cycles of denaturation, annealing, and extension (<xref ref-type="table" rid="t2">Table 2</xref>) as well as a final extension of 72 &#x000b0;C for seven min. PCR products (2-4 &#x003bc;l) were added to two volumes (4-8 &#x003bc;l) of SSCP stop solution consisting of 95% deionized formamide, 10 mM EDTA, 1 mg/ml Bromophenol blue, 1 mg/ml Xylene Cyanol (all these reagents were supplied by Sigma-Aldrich, St. Louis, MO), were denatured at 95 &#x000b0;C for ten min, and were chilled on ice for five min. The presence of abnormally migrating bands was confirmed by three different electrophoretic conditions using acrylamide gels (<xref ref-type="table" rid="t3">Table 3</xref>). Electrophoresis was performed on a DCode<sup>TM</sup> Universal Mutation Detection System (Bio-Rad, Hercules, CA) in 0.5X TBE buffer (45 mM Tris, 45 mM boric acid, 1 mM EDTA). After the run, gels were removed from the apparatus and the DNA bands were visualized by silver staining [<xref ref-type="bibr" rid="r20">20</xref>]. Mobility shift of single-strand DNA from the normal pattern indicated the presence of a possible mutation and was further investigated by sequence analysis of genomic DNA.</p><table-wrap id="t2" position="float"><label>Table 2</label><caption><title>Oligonucleotide primers used for amplification of the <italic>optineurin</italic> gene.</title></caption><table frame="hsides" rules="groups"><col width="44" span="1"/><col width="192" span="1"/><col width="76" span="1"/><col width="65" span="1"/><col width="64" span="1"/><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Exon</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Primer sequence (5'-3')</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Annealing temperature and time (C/s)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Extension time (s)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Amplicon length (bp)</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">F: GCCAGTGGG TTTGTGGGAC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">R: TGCAAAGGGATGGCATTTC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60/20<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">320<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">F: CACTTTCCTGGTGTGTGACTCC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">R: AAACAACATCACAATGGATCG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60/25<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">281<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">F: CCCAGCCTTAGTTTGATCTG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">R: GGGGAGGCTTTATAGTTTGC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60/20<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">278<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">F: CATATTGTGTTAAATCCCTTGC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">R: GGTCACAACATTTGACCTCC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60/20<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">198<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">F: AGTCTTTGGAATTTTTCTGATG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">R: ATGGGTGAACTGTATGGTATC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60/30<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">30<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">287<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">F: GCTATTTCTCTTAAAGCCAAAG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">R: ACTCTCGTGTGTGTGGGTG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60/30<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">14<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">205<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">10<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">F: GAGGTTTGTTTAATGTCAGATG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">R: TCAAAGGAGGATAAAATTGC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">55/30<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">30<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">211<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">11<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">F: CACTGCGACGTAAAGGAGC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">R: GCTGCCCTTCTGACTCAAC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">65/30<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">30<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">231<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">12<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">F: ATATTTTCCCCAGGATTCC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">R: AACGTTCAACAGTTTCTGTTC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">55/30<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">30<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">196<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">13<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">F: CAGGCAGAATTATTTCAAAAC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">R: AATACAGTCAGGGCTGGC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60/30<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">260<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">14<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">F: ACAGCACTACCTCCTCATCGC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">R: GATGTGAGCTCTGGGTCCTCC<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">65/30<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">231<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">15<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">F: TCAGTGTTGTCATGTTTCGGG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">R: TGAAAATCCAGGATCACACG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">60/30<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">30<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">171<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">16<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">F: CCTGCAAAATGGAACTAATGG<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">R: ACATTTACCAACAGTTTTGGG</td><td valign="top" align="left" rowspan="1" colspan="1">61/20</td><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">203</td></tr></tbody></table><table-wrap-foot><p>Annealing temperature and time, extension time for each primer pair and the predicted length for each of the PCR DNA products in base pairs (bp) are listed. In the Primer sequence column, F indicates forward and R indicates reverse.</p></table-wrap-foot></table-wrap><table-wrap id="t3" position="float"><label>Table 3</label><caption><title>Electrophoretic conditions used for single-stranded conformational polymorphism analysis.</title></caption><table frame="hsides" rules="groups"><col width="149" span="1"/><col width="81" span="1"/><col width="81" span="1"/><col width="72" span="1"/><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Acrylamide/bisacrylamide (10%)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Glycerol (%)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Temperature</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Voltage (V)</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">49/1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">RT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">300<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">29/1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">RT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">300<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">29/1</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">600</td></tr></tbody></table><table-wrap-foot><p>Acrylamide/bisacrylamide and glycerol composition of the gels as well as temperature and voltage used for electrophoresis are indicated.</p></table-wrap-foot></table-wrap></sec><sec><title>Linkage disequilibrium and haplotype construction</title><p>Pairwise linkage disequilibrium (LD) between the SNPs with minor allele frequencies (MAF) higher than 5% was measured as D' [<xref ref-type="bibr" rid="r21">21</xref>] using the <ext-link ext-link-type="uri" xlink:href="http://www.broad.mit.edu/personal/jcbarret/haploview/">Haploview</ext-link> software version 3.2 [<xref ref-type="bibr" rid="r22">22</xref>]. Regions of strong LD (LD blocks) were inferred using the confidence-interval model proposed by Gabriel and colleagues [<xref ref-type="bibr" rid="r23">23</xref>] as implemented in Haploview. Haplotype reconstruction was done with the expectation-maximization algorithm in <ext-link ext-link-type="uri" xlink:href="http://www.powermarker.net">PowerMarker</ext-link> v. 3.22 [<xref ref-type="bibr" rid="r24">24</xref>].</p></sec><sec><title>Statistical analysis</title><p>The significance of the difference in frequencies of DNA polymorphisms between patients and control subjects was determined by the x<sup>2</sup> test when all expected values were five or more. The Fisher's exact test was used when expected values were less than five. Data were statistically treated by using the SigmaStat 2.0 software (SPSS Science, Inc., Chicago, IL).</p></sec><sec><title>Expression of mutant myocilin in 293T cells</title><p>Myocilin point mutations were obtained as previously described [<xref ref-type="bibr" rid="r25">25</xref>]. The specific PCR primers used for mutagenesis were: 5'-CCA GAA CTG TCA TAA CAT ATG AGC TGA ATA CC-3' (forward) and 5'-GGT ATT CAG CTC ATA TGT TAT GAC AGT TCT GG-3' (reverse) for Arg346Thr; 5'-CAG CAG CAT GAT TGA CCA CAA CCC CCT GGA GAA G-3' (forward) and 5'-CTT CTC CAG GGG GTT GTG GTC AAT CAT GCT GCT G-3' (reverse) for Tyr479His.</p><p>Human embryonic kidney 293T cells were bought from the American Type Culture Collection (ATCC, Rockville, MD). Transient expression of wild-type and mutant myocilins was performed as described [<xref ref-type="bibr" rid="r25">25</xref>]. An expression analysis of the different myocilin forms was performed by western immunoblot using an anti-myc antibody (9E10, Santa Cruz, Valencia, CA) diluted at 1:400-1:500 [<xref ref-type="bibr" rid="r25">25</xref>]. Fluorescence microscopy was also carried out as described [<xref ref-type="bibr" rid="r25">25</xref>].</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Phenotype of patients</title><p>A total of 110 unrelated and sporadic POAG patients were studied. In addition, we analyzed 40 cases diagnosed with OHT. The control group included 98 individuals in whom glaucoma was ruled out. The main clinical features of most of these subjects have been reported in a previous study of <italic>CYP1B1</italic> mutations in Spanish patients with POAG [<xref ref-type="bibr" rid="r17">17</xref>]. Subjects with mutations in the <italic>CYP1B1</italic> gene were not included in the present study. The three groups were homogeneous with respect to gender and age (p&#x0003e;0.1; <xref ref-type="table" rid="t4">Table 4</xref>). Patients were under medical treatment to reduce IOP. Therefore, their IOP mean values were below 21 mmHg at the time of the study (<xref ref-type="table" rid="t4">Table 4</xref>), which indicated that treatment was effective. The mean IOP and C/D ratios in both eyes of glaucoma patients were significantly higher (p&#x0003c;0.01) than in controls (<xref ref-type="table" rid="t4">Table 4</xref>). The visual field status of the eyes from POAG patients was severe for 12.7%, moderate for 27.4%, early for 49.6%, and normal for 7.3%. The visual field could not be determined in 3.0% of eyes. Normal eyes were from patients who showed monolateral visual field alterations. The visual field was normal in the OHT patients.</p><table-wrap id="t4" position="float"><label>Table 4</label><caption><title>Clinical characteristics of participants in the study.</title></caption><table frame="hsides" rules="groups"><col width="111" span="1"/><col width="110" span="1"/><col width="110" span="1"/><col width="110" span="1"/><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Variable</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>OHT (n=40)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>POAG (n=110)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Control (n=98)</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age (mean&#x000b1;SD)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">56.5&#x000b1;11.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">62.2&#x000b1;11.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">61.1&#x000b1;12.6<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Female (%)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">47.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">48.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">51.1<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Male (%)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">52.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">51.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">48.9<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">IOP OD (mean&#x000b1;SD)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">17.6&#x000b1;4.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">17.7&#x000b1;3.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">15.1&#x000b1;3.1<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">IOP OS (mean&#x000b1;SD)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">17.8&#x000b1;4.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">17.3&#x000b1;3.0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">15.2&#x000b1;3.1<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">C/D OD (mean&#x000b1;SD)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.3&#x000b1;0.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.5&#x000b1;0.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.2&#x000b1;0.2<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">C/D OS (mean&#x000b1;SD)</td><td valign="top" align="left" rowspan="1" colspan="1">0.3&#x000b1;0.2</td><td valign="top" align="left" rowspan="1" colspan="1">0.5&#x000b1;0.2</td><td valign="top" align="left" rowspan="1" colspan="1">0.2&#x000b1;0.2</td></tr></tbody></table><table-wrap-foot><p>Details of clinical features of 40 OHT, 110 POAG patients, and 98 unaffected controls are shown in the table. Since this is a retrospective study, IOP values before medical treatment were generally not available. C/D indicates cup-disc ratio of optic nerve; OD indicates right eye; OS indicates left eye; and SD indicates standard deviation. The three groups were homogeneous with respect to gender and age. Mean IOP and C/D ratios in glaucoma patients were higher than in controls. In the "Variable" column, the listed age was at the time of the study.</p></table-wrap-foot></table-wrap></sec><sec><title>Identification of <italic>myocilin</italic> sequence variations and genotype-phenotype correlation</title><p>Genomic DNA from each of 110 POAG and 40 OHT unrelated Spanish patients was screened by direct PCR sequencing for mutations in the promoter (nucleotides -1 to -1117) and in the three exons including consensus splicing sequences of the <italic>MYOC</italic> gene. OHT patients were investigated because elevated IOP is one of the major risk factors for the development of glaucoma and in our group of POAG patients, OHT was the first stage of the disease. The same genetic analysis was performed in 98 control subjects. Allele and genotype frequencies for all sequence variations were calculated. Genotype frequencies did not deviate from the Hardy-Weinberg equilibrium (data not shown). We identified six common SNPs (MAF &#x0003e;5% in at least one group) in the promoter region: -1000C&#x0003e;G, -387C&#x0003e;T, -306G&#x0003e;A, -224T&#x0003e;C, -126T&#x0003e;C, and -83G&#x0003e;A (<xref ref-type="fig" rid="f1">Figure 1</xref> and <xref ref-type="table" rid="t5">Table 5</xref>). Two of them were located close to two consensus sequences: SNP -224T&#x0003e;C was mapped next to the 3' end of one negative glucocorticoid response element (nGRE) and SNP -83G&#x0003e;A was placed at the 3' end of a SAC box (<xref ref-type="fig" rid="f1">Figure 1</xref>). The two consensus sequences are putatively involved in the regulation of myocilin expression. The promoter polymorphism, -387C&#x0003e;T, was located in a mammalian interspersed repeat (MIR) element [<xref ref-type="bibr" rid="r26">26</xref>]. We also detected a polymorphic GT microsatellite at position -339 (<xref ref-type="fig" rid="f1">Figure 1</xref>) with seven alleles ranging from eleven to nineteen repetitions. Alleles 11, 16, and 19 presented the lowest frequencies in the three groups of subjects (0-1.6%) while allele 13 was the most frequent, ranging from 34.1% in POAG patients to 40.8% in controls (<xref ref-type="table" rid="t5">Table 5</xref>). Alleles 17 and 18 were not detected in our population. The genotype 13/15 was highly represented in the three groups and varied from 23.6% in POAG to 33.3% in OHT subjects (<xref ref-type="table" rid="t6">Table 6</xref>). This polymorphism has been previously described in Chinese [<xref ref-type="bibr" rid="r27">27</xref>] and Swedish [<xref ref-type="bibr" rid="r28">28</xref>] populations. We did not detect any statistically significant association between these <italic>MYOC</italic> promoter polymorphisms and either POAG or OHT (<xref ref-type="table" rid="t5">Table 5</xref> and <xref ref-type="table" rid="t6">Table 6</xref>). We also observed the common coding SNP, Arg76Lys, in this population (<xref ref-type="fig" rid="f1">Figure 1</xref>) with similar allele and genotype frequencies in cases and controls (<xref ref-type="table" rid="t5">Table 5</xref> and <xref ref-type="table" rid="t6">Table 6</xref>).</p><fig id="f1" fig-type="figure" position="float"><label>Figure 1</label><caption><p>Genomic structure of the human <italic>myocilin</italic> gene and location of identified DNA sequence variations. The promoter and the three exons are represented by boxes. Consensus regulatory sequences in the promoter region are depicted in the inset. Pathogenic mutations and polymorphisms in the coding region are indicated by solid and dashed arrows, respectively. Sequence variations in the promoter region are shown by arrowheads. Novel mutations are shown by asterisks. All mutations are defined in terms of the one-letter code. Designated features include AP-1-like and AP-2-like sequences, putative TATA and SAC boxes, glucocorticoid response element (GRE), negative glucocorticoid response element (nGRE), thyroid response element (TRE) and a MIR repeat [<xref ref-type="bibr" rid="r26">26</xref>,<xref ref-type="bibr" rid="r63">63</xref>]. -700_699ins: -700_699insCAGACACACATATACATGCACATACACA.</p></caption><graphic xlink:href="mv-v13-862-f1"/></fig><table-wrap id="t5" position="float"><label>Table 5</label><caption><title>Allele frequencies of <italic>myocilin</italic> promoter and coding sequence variations in primary open-angle glaucoma, adult-onset ocular hypertension, and control subjects.</title></caption><table frame="hsides" rules="groups"><col width="86" span="1"/><col width="58" span="1"/><col width="62" span="1"/><col width="60" span="1"/><col width="62" span="1"/><col width="55" span="1"/><col width="55" span="1"/><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Polymorphism</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Allele</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>POAG (%) (n=220)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>OHT (%) (n=80)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Control (%) (n=196)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>P*</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>P#</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">-1000C&#x0003e;G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">C<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">90<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">88.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">86.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.29<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.64<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">13.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">-700_699ins<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">WT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">99.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.28<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">I<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">-387C&#x0003e;T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">C<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">89.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">88.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">86.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.37<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.64<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">13.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">-339(GT)11-19<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.14<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.48<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">16.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">16.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">13<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">34.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">40<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">40.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">14<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">27.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">15<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">19.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">15<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">27.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">26.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">22.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">16<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">19<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">-315G&#x0003e;A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">99.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.28<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">-306G&#x0003e;A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">80.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">85<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">81.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.53<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">19.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">15<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">18.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">-224T&#x0003e;C<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">80<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">71.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">69.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.06<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.8<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">C<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">28.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">30.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">-190G&#x0003e;T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">99.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.39<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.28<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">-126T&#x0003e;C<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">97.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">95<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">98.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.21<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">C<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">-83G&#x0003e;A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">88.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">93.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">87.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.1<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">c.250G&#x0003e;A (Arg76Lys)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">89<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">95<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">89.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.87<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.1<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">c.499A&#x0003e;G (Leu159Leu)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">97.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.08<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">c.520G&#x0003e;C (Leu166Leu)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">98.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.28<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">C<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">c.877G&#x0003e;T (Thr285Thr)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">99.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.47<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.28<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">c.997G&#x0003e;A (Thr325Thr)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">99.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">98.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">99.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.48<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">c.1063T&#x0003e;C (Tyr347Tyr)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">99.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">95<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">99<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.31<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">C<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">C.12145A&#x0003e;G (Lys398Arg)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">99.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.47<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.28<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">G</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0.5</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>The full description of -700_699ins is -700_699insCAGACACACATATACATGCACATACACA. In the table, I indicates the insertion allele, WT indicates the wild-type allele, and n is the total number of chromosomes. The asterisk indicates POAG versus controls and the sharp (hash mark) indicates OHT versus controls.</p></table-wrap-foot></table-wrap><table-wrap id="t6" position="float"><label>Table 6</label><caption><title>Genotype frequencies of <italic>myocilin</italic> promoter and coding sequence variations in primary open-angle glaucoma, adult-onset ocular hypertension, and control subjects.</title></caption><table frame="hsides" rules="groups"><col width="86" span="1"/><col width="84" span="1"/><col width="59" span="1"/><col width="55" span="1"/><col width="59" span="1"/><col width="48" span="1"/><col width="48" span="1"/><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Polymorphism</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Allele1/Allele2</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>POAG (%) (n=110)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>OHT (%) (n=40)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Control (%) (n=98)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>P*</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>P#</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">-1000C&#x0003e;G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">C/C<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">80<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">82.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">86.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.26<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.12<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">C/G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">13.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G/G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">-700_699ins#<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">WT/WT<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">97.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.28<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">WT/I<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">I/I<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">-387C&#x0003e;T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">C/C<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">80<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">82.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">86.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.12<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">C/T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">19<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">13.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">T/T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">-339(GT)11-19<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11/15<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.44<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.47<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12/13<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">18.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">33.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">30.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12/14<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12/15<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">13/14<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">24.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">22.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">13/15<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">23.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">33.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">27.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">13/16<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">13/19<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">14/15<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">27.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">15.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">15/16<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">-315G&#x0003e;A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G/G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">97.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G/A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">A/A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">-306G&#x0003e;A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G/G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">64.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">65<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">64.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.74<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">A/G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">33.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">32.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">34.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">A/A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">-224 T&#x0003e;C<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">T/T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">62.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">55<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">49<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.7<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">C/T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">34.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">32.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">41.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">C/C<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">12.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">-190G&#x0003e;T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G/G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">99<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.47<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G/T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">T/T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">-126T&#x0003e;C<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">T/T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">95.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">90<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">96.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.69<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.21<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">C/T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">C/C<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">-83G&#x0003e;A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G/G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">78.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">88.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">76.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.94<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.24<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">A/G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">21<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">22.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">A/A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">c.250G&#x0003e;A (Arg76Lys)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G/G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">79<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">89<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">79.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.27<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">A/G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">19.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">A/A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">c.499A&#x0003e;G (Leu159Leu)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">A/A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">99<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">97.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.28<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">A/G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G/G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">c.520G&#x0003e;C (Leu166Leu)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G/G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">99<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G/C<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">C/C<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">c.877G&#x0003e;T (Thr285Thr)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G/G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">97.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">99<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.47<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.2<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G/T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">T/T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">c.997G&#x0003e;A (Thr325Thr)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G/G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">97<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">97.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">99<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.62<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.47<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G/A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2.5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">A/A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">c.1063T&#x0003e;C (Tyr347Tyr)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">T/T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">96.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">95<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">98<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.68<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.32<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">T/C<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">C/C<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">C.1215A&#x0003e;G (Lys398Arg)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">A/A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">99<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.47<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">A/G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">G/G</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>The full description of -700_699ins is -700_699insCAGACACACATATACATGCACATACACA. In the table, I indicates the insertion allele, WT indicates the wild-type allele, and n is the total number of chromosomes. The asterisk indicates POAG versus controls and the sharp (hash mark) indicates OHT versus controls.</p></table-wrap-foot></table-wrap><p>In addition, nine sequence variations with MAFs greater than or equal to 5% were identified: -700_699ins, -315G&#x0003e;A, -190G&#x0003e;T, c.499A&#x0003e;G (Leu159Leu), c.520G&#x0003e;C (Leu166Leu), c.877G&#x0003e;T (Thr285Thr), c.997G&#x0003e;A (Thr325Thr), c.1063T&#x0003e;C (Tyr347Tyr), and c.1215A&#x0003e;G (Lys398Arg; <xref ref-type="fig" rid="f1">Figure 1</xref> and <xref ref-type="table" rid="t5">Table 5</xref>). The last SNP was detected only in a control subject (<xref ref-type="table" rid="t5">Table 5</xref> and <xref ref-type="table" rid="t6">Table 6</xref>). To the best of our knowledge two of these SNPs (-315G&#x0003e;A and -190G&#x0003e;T) and the 28 bp insertion (-700_699insCAGACACACATATACATGCACATACACA) have not been previously described. They were found in two different OHT patients (-315G&#x0003e;A and -700_699ins) and in one control subject (-190G&#x0003e;T; <xref ref-type="table" rid="t5">Table 5</xref> and <xref ref-type="table" rid="t6">Table 6</xref>). The 28 bp insertion was located in an AP1-like sequence (<xref ref-type="fig" rid="f1">Figure 1</xref>). Of the remaining six rare polymorphisms, five were synonymous mutations (Leu159Leu, Leu166Leu, Thr285Thr, Thr325Thr, and Tyr347Tyr), while one (Lys398Arg) originated a conservative amino acid substitution (<xref ref-type="fig" rid="f1">Figure 1</xref>). All of them except Leu166Leu have been previously reported [<xref ref-type="bibr" rid="r8">8</xref>,<xref ref-type="bibr" rid="r29">29</xref>]. Association analysis of these polymorphisms with the disease was limited by their low frequencies (<xref ref-type="table" rid="t5">Table 5</xref> and <xref ref-type="table" rid="t6">Table 6</xref>).</p></sec><sec><title><italic>Myocilin</italic> linkage disequilibrium structure</title><p>To determine the linkage disequilibrium (LD) structure of the <italic>MYOC</italic> gene in our population, we evaluated in the control group pairwise LD between all SNPs with MAF &#x0003e;5%. Two LD blocks were detected (<xref ref-type="fig" rid="f2">Figure 2</xref>). Block 1 comprises SNPs -1000C&#x0003e;G and -387C&#x0003e;T (D'=1.0; D' confidence bounds=0.88-1.0) while block 2 is composed of SNPs -83G&#x0003e;A and Arg76Lys (D'=0.95; D' confidence bounds=0.80-0.99). The same LD structure was observed in glaucoma patients (data not shown).</p><fig id="f2" fig-type="figure" position="float"><label>Figure 2</label><caption><p>Pairwise linkage disequilibrium pattern of <italic>myocilin</italic> single nucleotide polymorphisms measured by D'. The location of each tested SNP along the <italic>MYOC</italic> gene is indicated at the top. The strength of LD is depicted by grey intensity, which moves from light grey to black as D' progresses from 0 to 1.</p></caption><graphic xlink:href="mv-v13-862-f2"/></fig></sec><sec><title>Haplotype analysis</title><p><italic>MYOC</italic> SNPs with MAF &#x0003e;5% were used to construct predicted haplotypes, taking into account only one SNP from each LD block (-1000C &#x0003e;G from block 1 and -83G&#x0003e;A from block 2). Twenty haplotypes with frequencies &#x0003e;2% were inferred from our data, but only five exhibited frequencies &#x0003e;5% in the three groups (<xref ref-type="table" rid="t7">Table 7</xref>). The rare inferred haplotypes (&#x0003c;5%) were pooled in one class to allow comparison between cases and controls. We did not find any significant differences in predicted haplotype frequencies between cases and controls (<xref ref-type="table" rid="t7">Table 7</xref>), which indicates that they do not contribute to the development of glaucoma.</p><table-wrap id="t7" position="float"><label>Table 7</label><caption><title>Frequencies of <italic>myocilin</italic> inferred haplotypes in primary open-angle glaucoma, adult-onset ocular hypertension, and control subjects.</title></caption><table frame="hsides" rules="groups"><col width="78" span="1"/><col width="74" span="1"/><col width="72" span="1"/><col width="75" span="1"/><col width="72" span="1"/><col width="71" span="1"/><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Haplotype</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>POAG (%)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>OHT (%)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Control (%)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>p*</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>p#</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">H9 (C-13-G-T-T-G)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">19.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">21.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">21.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.055<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.83<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">H7 (C-13-G-C-T-G)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">14.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">21.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">H15 (C-15-A-T-T-G)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">13.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">16.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">H18 (G-15-G-T-T-G)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">14.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">9.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6.1<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">H4 (C-12-G-T-T-G)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">7.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Rest of haplotypes</td><td valign="top" align="left" rowspan="1" colspan="1">35.4</td><td valign="top" align="left" rowspan="1" colspan="1">27.6</td><td valign="top" align="left" rowspan="1" colspan="1">30</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>Haplotypes were constructed with polymorphisms, -1000, -339(GT)11-19, -306, -224, -126 and -83. Predicted haplotypes with frequencies lower than 2% were not considered. Only haplotypes with frequencies higher than 5% in all groups are shown. The asterisk indicates POAG versus controls and the sharp (hash mark) indicates OHT versus controls.</p></table-wrap-foot></table-wrap></sec><sec><title>Identification of <italic>myocilin</italic> pathogenic mutations in sporadic primary open-angle glaucoma cases</title><p>One non-sense (Gln368stop) and two missense (Ala445Val and Tyr479His) mutations were identified in three POAG patients (2.7%; <xref ref-type="fig" rid="f1">Figure 1</xref> and <xref ref-type="table" rid="t8">Table 8</xref>). All of them were present in heterozygosis and affected amino acid positions located in the olfactomedin-like domain (exon 3) of myocilin. Two of these mutations (Gln368Stop and Ala445Val) were previously reported in POAG [<xref ref-type="bibr" rid="r8">8</xref>,<xref ref-type="bibr" rid="r30">30</xref>] and as far as we know, the third mutation (Tyr479His) has been detected for the first time in the present study. Ages at diagnosis ranged from 32 to 56 years in this group of POAG patients (mean of 51.6 years; <xref ref-type="table" rid="t8">Table 8</xref>). In our sample, the mutation Gln368Stop (patient number 67) was associated with a severe phenotype featured by severe visual field alteration, high optic disk excavation, and resistance to medical treatment, which requires filtration surgery for an adequate control of IOP (<xref ref-type="table" rid="t8">Table 8</xref>). Carriers of mutations Ala445Val (patient number 50) and Tyr479His (patient number 3) showed early alteration of the visual field and their IOPs were adequately controlled with drugs (<xref ref-type="table" rid="t8">Table 8</xref>). The Tyr479His mutation was associated with an early-onset of the disease (32 years). Additionally, we also found the novel myocilin mutation Arg346Thr in patient number 19 who was diagnosed with glaucoma at 44 years and showed a narrow-angle (<xref ref-type="table" rid="t8">Table 8</xref>). Due to the narrow-angle, this patient was not included in the group of POAG subjects carrying <italic>MYOC</italic> mutations. After diagnosis, this subject underwent Nd:YAG laser iridotomy to prevent acute angle-closure glaucoma followed by treatment with three drugs (pilocarpine, dorzolamide, and timolol) to reduce IOP. In spite of this treatment, he required filtration surgery for the correct control of IOP. After 22 years of evolution, this patient displayed an extreme clinical phenotype characterized by bilateral and severe visual field alteration and large C/D ratios (<xref ref-type="table" rid="t8">Table 8</xref>).</p><table-wrap id="t8" position="float"><label>Table 8</label><caption><title>Clinical features of glaucoma patients with pathogenic <italic>myocilin</italic> mutations.</title></caption><table frame="hsides" rules="groups"><col width="69" span="1"/><col width="51" span="1"/><col width="38" span="1"/><col width="58" span="1"/><col width="49" span="1"/><col width="54" span="1"/><col width="56" span="1"/><col width="77" span="1"/><col width="74" span="1"/><col width="86" span="1"/><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Mutation</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Subject number</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Age at time of the study</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Age at diagnosis</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Gender</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>IOP OD/OS (mmHg)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>C/D Ratio (OD/OS)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Visual field alteration (OD/OS)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Iridocorneal angle</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Treatment (number of drugs)/surgery</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">R346T* c.1059 G&#x0003e;C)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">19<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">66<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">44<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">10/10<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.9/0.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Severe/severe<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1/2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">3/Yes<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Q368Stop c.1124C&#x0003e;T)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">67<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">68<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">56<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">M<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">20/16<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.9/0.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Severe/severe<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2/Yes<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">A445V c.1356 C&#x0003e;T)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">50<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">72<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">67<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">F<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">15/15<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">ND/ND<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Early/early<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">2/No<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Y479H* c.1457 T&#x0003e;C)</td><td valign="top" align="left" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1">40</td><td valign="top" align="left" rowspan="1" colspan="1">32</td><td valign="top" align="left" rowspan="1" colspan="1">M</td><td valign="top" align="left" rowspan="1" colspan="1">14/16</td><td valign="top" align="left" rowspan="1" colspan="1">0.4/0.4</td><td valign="top" align="left" rowspan="1" colspan="1">Early/early</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">1/No</td></tr></tbody></table><table-wrap-foot><p>Mutation information was based on the <italic>MYOC</italic> GenBank accession number: <ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/external.cgi?gbdna=NM_000261">NM_000261</ext-link>. IOP values were obtained following medical treatment. IOP records before treatment were not always available. The asterisk indicates novel mutations. IOP: intraocular pressure, OD: right eye, OS: left eye, C/D: cup-disc ratio of optic nerve, ND: not determined due to oblique insertion of the optic nerve head.</p></table-wrap-foot></table-wrap></sec><sec><title>Evaluation of the two novel myocilin mutations pathogenicity by multiple sequence alignment and transient expression in 293T cells</title><p>We used three approaches to evaluate the pathogenicity of the novel mutations: (a) analysis of evolutionary conservation of affected amino acids; (b) prediction of physicochemical changes induced by the different mutations; and (c) study of expression and subcellular distribution of cloned mutant and wild-type myocilin in transiently transfected 293T cells. Comparison of amino acid sequence alignment among myocilin from different species as well as with other members of the olfactomedin family of human proteins (olfactomedin-1 and optimedin) showed that the two novel mutations affected highly conserved amino acid residues (Arg346 and Tyr479), which are located in two regions of predicted beta-sheet folding (<xref ref-type="fig" rid="f3">Figure 3</xref>). In addition, the two novel non-conservative mutations altered the predicted physicochemical properties of the polypeptide chain. The positive charge of Arg at position 346 is substituted by the polar Thr side chain in the mutant protein. Similarly, the hydrophobic Tyr is replaced by the polar His residue at amino acid position 479. These predicted amino acid changes could disrupt the secondary structure of myocilin, resulting in protein misfolding.</p><fig id="f3" fig-type="figure" position="float"><label>Figure 3</label><caption><p>Multiple amino acid sequence alignment of myocilin from different species. Sequence alignment was generated by <ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/clustalw/">ClustalW</ext-link>. Residues affected by mutations are indicated by arrowheads. Asterisks indicate amino acid positions at which all query sequences are identical. Amino acid positions at which all analyzed sequences have amino acids that are chemically similar are denoted by two dots (:). One dot denotes amino acid positions with weak chemical similarity (.). Arrows indicated regions of the polypeptide chain which are predicted to fold into a beta-sheet conformation.</p></caption><graphic xlink:href="mv-v13-862-f3"/></fig><p>Transient expression of the two novel missense myocilin mutants in 293T cells showed that they accumulated intracellularly, mainly in the insoluble cellular fraction (<xref ref-type="fig" rid="f4">Figure 4</xref>). The same behavior was observed with the myocilin mutation, Pro370Leu, which was used as a control because it is associated with one of the most severe myocilin glaucoma phenotypes [<xref ref-type="bibr" rid="r31">31</xref>]. A 35 kDa myocilin fragment was present in the culture medium of cells expressing wild-type myocilin (<xref ref-type="fig" rid="f4">Figure 4</xref>, culture medium lanes), which is produced by proteolytic cleavage of the protein [<xref ref-type="bibr" rid="r25">25</xref>]. This fragment was neither detected in the two myocilin mutants nor in the control mutation, Pro370Leu (<xref ref-type="fig" rid="f4">Figure 4</xref>), indicating that the proteolytic processing is reduced by these mutations, as previously described for myocilin pathogenic mutations [<xref ref-type="bibr" rid="r25">25</xref>].</p><fig id="f4" fig-type="figure" position="float"><label>Figure 4</label><caption><p>Western immunoblot of two novel myocilin mutations found in this study and expressed in transiently transfected 293T cells. Two hundred nanograms of DNA constructs encoding myc epitope-tagged versions of mutant myocilin forms (Arg346Thr, Tyr479His, Gln368Stop and Pro370Leu) were transfected into 293T cells. Separation of culture medium, soluble cellular fractions, and insoluble cellular fractions were carried out as indicated in the Materials and Methods. Detection was performed with an anti-myc monoclonal antibody. Myc-tagged wild-type myocilin was used as a control of normal expression and the myocilin mutation Pro370Leu was employed as a control of disease-causing mutation. The arrow and arrowhead indicate the position of the 55 kDa and 35 kDa myocilin bands, respectively. c.m.: culture medium; s.c.f.: soluble cellular fraction; i.c.f.: insoluble cellular fraction.</p></caption><graphic xlink:href="mv-v13-862-f4"/></fig><p>Immunocytochemical analysis of the two novel mutant myocilins transiently expressed in 293T cells revealed intense granular signals in the cytoplasm (<xref ref-type="fig" rid="f5">Figure 5B</xref> and <xref ref-type="fig" rid="f5">Figure 5C</xref>). This indicates most of the mutant myocilins accumulated intracellularly in the ER as misfolded proteins. This staining pattern clearly contrasted with that of wild-type myocilin, which was distributed in a reticular network located around the nucleus and cytoplasm and labeled a perinuclear structure compatible with the Golgi apparatus (<xref ref-type="fig" rid="f5">Figure 5A</xref>). These results agree with previous reports [<xref ref-type="bibr" rid="r25">25</xref>,<xref ref-type="bibr" rid="r32">32</xref>-<xref ref-type="bibr" rid="r36">36</xref>] and strongly support that the two novel mutations found in the glaucoma patients are pathogenic.</p><fig id="f5" fig-type="figure" position="float"><label>Figure 5</label><caption><p>Subcellular distribution in transiently transfected 293T cells of human wild-type myocilin-GFP and two novel myocilin mutations found in this study. Two hundred nanograms of DNA constructs encoding wild-type myocilin (<bold>A</bold>), mutant myocilin forms, Arg346Thr (<bold>B</bold>) and Tyr479His (<bold>C</bold>), and the control, Pro370Leu (a disease causing mutation; <bold>D</bold>) were transfected into 293T cells. Wild-type myocilin was mainly detected in structures compatible with the Golgi apparatus and secretory vesicles. Note that the three mutant versions accumulated in the ER. The asterisk indicates the location of the Golgi apparatus. Arrows indicate the position of intracellular myocilin aggregates. Original magnification: X1600.</p></caption><graphic xlink:href="mv-v13-862-f5"/></fig></sec><sec><title>Analysis of <italic>optineurin</italic> sequence variations in sporadic cases of primary open-angle glaucoma</title><p>To evaluate the role of <italic>OPTN</italic> DNA sequence variations in Spanish patients affected by POAG, we screened the complete coding region of the gene in cases and controls by SSCP. Analysis by PCR DNA sequencing of the SSCP positive samples revealed two different G&#x0003e;A transitions, which originated two synonymous SNPs: Thr34Thr and Leu41Leu (<xref ref-type="table" rid="t9">Table 9</xref>). Both SNPs mapped to exon 4 and have been previously described in other populations [<xref ref-type="bibr" rid="r18">18</xref>,<xref ref-type="bibr" rid="r37">37</xref>-<xref ref-type="bibr" rid="r40">40</xref>]. Thr34Thr is a common polymorphism in our population, whereas Leu41Leu is a relatively rare one with MAFs of 1.8% and 2.6% in POAG and controls, respectively (<xref ref-type="table" rid="t9">Table 9</xref>). The low frequency allele (A) was not detected in the OHT group. Their genotype frequencies are shown in <xref ref-type="table" rid="t10">Table 10</xref>. There were no statistically significant differences in either allele or genotype frequencies between cases and controls (<xref ref-type="table" rid="t8">Table 8</xref> and <xref ref-type="table" rid="t9">Table 9</xref>). These data indicate that <italic>OPTN</italic> DNA sequence variations are not involved in high-pressure POAG in the Spanish population.</p><table-wrap id="t9" position="float"><label>Table 9</label><caption><title>Allele frequencies of <italic>optineurin</italic> single nucleotide polymorphisms in primary open-angle glaucoma, adult-onset ocular hypertension, and control subjects.</title></caption><table frame="hsides" rules="groups"><col width="86" span="1"/><col width="58" span="1"/><col width="62" span="1"/><col width="60" span="1"/><col width="62" span="1"/><col width="55" span="1"/><col width="55" span="1"/><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Polymorphism</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Allele</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>POAG (%) (n=220)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>OHT (%) (n=80)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Control (%) (n=196)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>p*</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>p#</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">c.412G&#x0003e;A (Thr34Thr)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">66.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">75<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">65.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.82<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.11<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">33.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">25<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">34.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">c.433G&#x0003e;A (Leu41Leu)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">98.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">97.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.74<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.32<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1">1.8</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">2.6</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>A &#x003c7;<sup>2</sup> test or Fisher's exact test was used to compare allele frequencies in POAG or OHT patients with control subjects. Allele frequencies do not statistically differ between cases and controls. The asterisk indicates POAG versus controls and the sharp (hash mark) indicates OHT versus controls.</p></table-wrap-foot></table-wrap><table-wrap id="t10" position="float"><label>Table 10</label><caption><title>Genotype frequencies of <italic>optineurin</italic> single nucleotide polymorphisms in primary open-angle glaucoma, adult-onset ocular hypertension, and control subjects.</title></caption><table frame="hsides" rules="groups"><col width="69" span="1"/><col width="84" span="1"/><col width="61" span="1"/><col width="58" span="1"/><col width="61" span="1"/><col width="53" span="1"/><col width="53" span="1"/><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>SNP</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Allele1/Allele2</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>POAG (%) (n=110)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>OHT (%) (n=40)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Control (%) (n=98)</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>p*</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>p#</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">c.412G&#x0003e;A (Thr34Thr)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G/G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">44.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">56.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">49.9<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.06<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.2<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G/A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">44.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">36.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">31<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">A/A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">11.4<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">6.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">19<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">c.433G&#x0003e;A (Leu41Leu)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G/G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">98.2<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">100<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">94.6<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.25<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0.32<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">G/A<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1.8<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">0<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">5.3<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">A/A</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>A &#x003c7;<sup>2</sup> test or Fisher's exact test was used to compare genotype frequencies in POAG or OHT patients with control subjects. Genotype frequencies do not statistically differ between cases and controls. The asterisk indicates POAG versus controls and the sharp (hash mark) indicates OHT versus controls.</p></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Information regarding the role of <italic>MYOC</italic> and <italic>OPTN</italic> in Spanish POAG patients is scarce. So, the contribution of <italic>OPTN</italic> sequence variations to POAG in Spain has not been analyzed so far. Therefore, the main purpose of this study was to analyze the contribution of <italic>MYOC</italic> and <italic>OPTN</italic> sequence variations to adult-onset glaucoma in patients from this country.</p><p>We have found that heterozygous glaucoma <italic>MYOC</italic> mutations are located in the olfactomedin-like domain in 2.7% of POAG patients from Southeast Spain in accordance with frequencies reported in other populations [<xref ref-type="bibr" rid="r9">9</xref>,<xref ref-type="bibr" rid="r29">29</xref>]. One of the most interesting findings of this study was the identification of the novel mutation Tyr479His in an early-onset glaucoma patient with a mild phenotype. The high evolutionary conservation of the affected amino acid residue together with the biochemical and microscopy analysis supports the pathogenicity of this mutation. Two of the identified mutations, Gln368Stop and Ala445Val, have been previously described. Gln368Stop is the most common myocilin mutation found in POAG [<xref ref-type="bibr" rid="r8">8</xref>,<xref ref-type="bibr" rid="r29">29</xref>]. Interestingly, it is generally associated with late glaucoma onset (mean age at diagnosis 54.9 years) and low IOPs compared to other <italic>MYOC</italic> mutations [<xref ref-type="bibr" rid="r41">41</xref>]. Carriers of this mutation also show adequate responses to medical treatment similar to ordinary adult-onset POAG patients [<xref ref-type="bibr" rid="r8">8</xref>,<xref ref-type="bibr" rid="r9">9</xref>,<xref ref-type="bibr" rid="r29">29</xref>,<xref ref-type="bibr" rid="r30">30</xref>,<xref ref-type="bibr" rid="r41">41</xref>,<xref ref-type="bibr" rid="r42">42</xref>]. In contrast, our study found that Gln368Stop was associated with severe optic disk and visual damage and the patient who carried the mutation required surgery for a correct control of IOP. Since diagnosis was performed timely (at 56 years) further work is necessary to determine whether the phenotype is directly caused by this mutation or if it is influenced by other genetic and/or environmental factors.</p><p>Mutation Ala445Val has been previously found in OHT [<xref ref-type="bibr" rid="r43">43</xref>] and POAG patients from different populations [<xref ref-type="bibr" rid="r8">8</xref>,<xref ref-type="bibr" rid="r44">44</xref>]. The case subject who harboured this predicted amino acid substitution (number 50) showed a mild glaucoma phenotype. Noteworthy, a second novel mutation, Arg346Thr, was found in a patient with a narrow-angle. For this reason, it was not considered as a mutation found in POAG patients. Interestingly, this subject was diagnosed with glaucoma at 44 years of age, in contrast with typical closure-angle glaucoma which usually manifests at older ages. Preventive iridotomy to prevent pupillary block, followed by medical treatment with three drugs were not sufficient to reduce IOP thus required filtration surgery. These data indicate that the narrow angle is not the primary cause of glaucoma in this patient. Furthermore, it has been reported that myocilin mutations are not associated with angle-closure glaucoma, at least in Chinese patients [<xref ref-type="bibr" rid="r45">45</xref>]. Altogether, these data suggest that the narrow angle and the myocilin mutation could be coincidental in this patient and that Tyr479His could be involved in POAG development. Further investigations are required to determine the exact role of this mutation in POAG.</p><p>A previous study identified 7.5% of <italic>MYOC</italic> mutation carriers in patients from Galicia (N. Spain), but only sequence variations in exon 3 were analyzed [<xref ref-type="bibr" rid="r46">46</xref>]. Apart from Gln368Stop, which has also been identified by Vazquez and co-workers, the spectrum of pathogenic mutations was different from that found in the present study. It remains to be investigated whether these differences can be attributed to different genetic backgrounds between these two Spanish subpopulations or to the sample size used in the two studies. The same researchers later analyzed <italic>MYOC</italic> mutations in exons 1 and 2 and in the promoter region of this group of patients. No mutations in these two exons were found, and although five sequence variations were identified in the promoter region, no association with the disease was established [<xref ref-type="bibr" rid="r47">47</xref>], which agrees with our results.</p><p>In a previous study we found that approximately 10% of Spanish POAG patients carry mutations in the <italic>CYP1B1</italic> gene [<xref ref-type="bibr" rid="r17">17</xref>], which is three times higher than the frequency of carriers of mutations in the <italic>MYOC</italic> gene. This data clearly shows the existence of genetic heterogeneity among Spanish POAG patients and indicates that <italic>CYP1B1</italic> sequence alterations are the most important genetically known cause of POAG, at least in our population.</p><p>In the present study we have identified 15 <italic>MYOC</italic> SNPs, one polymorphic GT microsatellite, and one 28 bp insertion. All these DNA sequence variations were distributed along the promoter and coding region of the gene. To the best of our knowledge, three of these SNPs (-315G&#x0003e;A, -190G&#x0003e;T, and Leu166Leu) and the -700_699ins have been identified here for the first time. None of the polymorphic DNA sequence variations showed significant association with glaucoma. Albeit some of these promoter SNPs were located in putative regulatory promoter sequences, it remains to be demonstrated whether they affect <italic>MYOC</italic> expression. In any event, it is unlikely that changes in the gene expression may contribute to myocilin glaucoma since development of the disease appears to be related with structural alterations of the protein [<xref ref-type="bibr" rid="r34">34</xref>,<xref ref-type="bibr" rid="r48">48</xref>,<xref ref-type="bibr" rid="r49">49</xref>].</p><p>In accordance with previous reports, we found that allele and genotype frequencies of SNP -1000C&#x0003e;G were not significantly different in cases and controls [<xref ref-type="bibr" rid="r50">50</xref>-<xref ref-type="bibr" rid="r52">52</xref>]. Since Colomb et al reported the association of this SNP with the severity of POAG, there has been some controversy about the actual relationship with the disease. Our data support that there is no association between this polymorphism and the disease in Spanish patients.</p><p>We detected two LD blocks composed of SNPs -1000C&#x0003e;G and -387C&#x0003e;T (block 1) and -83G&#x0003e;A and Arg76Lys (block 2). LD block 1 has been described in the Chinese population [<xref ref-type="bibr" rid="r53">53</xref>] whereas LD block 2 has been found in Asian [<xref ref-type="bibr" rid="r53">53</xref>-<xref ref-type="bibr" rid="r58">58</xref>] and European populations [<xref ref-type="bibr" rid="r10">10</xref>]. Analysis of inferred six loci haplotypes further confirmed no association of <italic>MYOC</italic> promoter polymorphisms with either OHT or POAG in the studied Spanish population.</p><p>Defects in <italic>OPTN</italic> have been clearly implicated in normal tension glaucoma (NTG) [<xref ref-type="bibr" rid="r18">18</xref>,<xref ref-type="bibr" rid="r40">40</xref>], but its role in high-pressure glaucoma has been a source of controversy [<xref ref-type="bibr" rid="r59">59</xref>-<xref ref-type="bibr" rid="r61">61</xref>]. In accordance with previous reports, our data indicate that <italic>OPTN</italic> does not contribute to the development of either OHT or typical adult-onset high-pressure glaucoma, at least in the Spanish population [<xref ref-type="bibr" rid="r62">62</xref>].</p><p>The present study provides new insight into the role of <italic>MYOC</italic> and <italic>OPTN</italic> genes in POAG in Spain and brings new information to unravel genetic alterations associated with POAG in this country.</p></sec></body><back><ack><title>Acknowledgements</title><p>We thank Dr. Juan L&#x000f3;pez-Moya, Chairman of the "Servicio de Oftalmolog&#x000ed;a, Complejo Hospitalario Universitario de Albacete" and Dr. Ricardo Fraile-Fresno for supporting this project. We also thank Mrs. Ana Mar&#x000ed;a Alonso and Mrs. Carmen Cifuentes for technical assistance and the nurses of the "Servicio de Oftalmolog&#x000ed;a" for extracting blood samples. We are also indebted to Mr. Jos&#x000e9; Daniel Aroca-Aguilar for his invaluable collaboration in DNA sequencing. We wish to cordially thank patients and control subjects for their cooperation in the study. Supported in part by research grants PI052494, 02021- 00, and PAI-02-049 from the "Fondo de Investigaciones Sanitarias", "Consejer&#x000ed;a de Sanidad", and "Consejer&#x000ed;a de Ciencia y Tecnolog&#x000ed;a de la Junta de Comunidades de Castilla-La Mancha", respectively (to J.E.); and from NIH grant EY04873 and a Research to Prevent Blindness Lew Waserman Merit Award (to M.C-P.). Mar&#x000ed;a-Pilar L&#x000f3;pez-Garrido was a recipient of a fellowship from the "Consejer&#x000ed;a de Sanidad de la Junta de Comunidades de Castilla-La Mancha". The authors have no financial or proprietary conflicts relevant to the content of this paper.</p></ack><ref-list><title>References</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quigley</surname><given-names>HA</given-names></name><name><surname>Nickells</surname><given-names>RW</given-names></name><name><surname>Kerrigan</surname><given-names>LA</given-names></name><name><surname>Pease</surname><given-names>ME</given-names></name><name><surname>Thibault</surname><given-names>DJ</given-names></name><name><surname>Zack</surname><given-names>DJ</given-names></name></person-group><article-title>Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis.</article-title><source>Invest Ophthalmol Vis Sci</source><year>1995</year><volume>36</volume><fpage>774</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">7706025</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quigley</surname><given-names>HA</given-names></name><name><surname>Katz</surname><given-names>J</given-names></name><name><surname>Derick</surname><given-names>RJ</given-names></name><name><surname>Gilbert</surname><given-names>D</given-names></name><name><surname>Sommer</surname><given-names>A</given-names></name></person-group><article-title>An evaluation of optic disc and nerve fiber layer examinations in monitoring progression of early glaucoma damage.</article-title><source>Ophthalmology</source><year>1992</year><volume>99</volume><fpage>19</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">1741133</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitazawa</surname><given-names>Y</given-names></name><name><surname>Horie</surname><given-names>T</given-names></name><name><surname>Aoki</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Nishioka</surname><given-names>K</given-names></name></person-group><article-title>Untreated ocular hypertension. A long-term prospective study.</article-title><source>Arch Ophthalmol</source><year>1977</year><volume>95</volume><fpage>1180</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">880076</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quigley</surname><given-names>HA</given-names></name></person-group><article-title>Neuronal death in glaucoma.</article-title><source>Prog Retin Eye Res</source><year>1999</year><volume>18</volume><fpage>39</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">9920498</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moenkemann</surname><given-names>H</given-names></name><name><surname>Flammer</surname><given-names>J</given-names></name><name><surname>Wunderlich</surname><given-names>K</given-names></name><name><surname>Breipohl</surname><given-names>W</given-names></name><name><surname>Schild</surname><given-names>HH</given-names></name><name><surname>Golubnitschaja</surname><given-names>O</given-names></name></person-group><article-title>Increased DNA breaks and up-regulation of both G(1) and G(2) checkpoint genes p21(WAF1/CIP1) and 14-3-3 sigma in circulating leukocytes of glaucoma patients and vasospastic individuals.</article-title><source>Amino Acids</source><year>2005</year><volume>28</volume><fpage>199</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">15723242</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Challa</surname><given-names>P</given-names></name><name><surname>Herndon</surname><given-names>LW</given-names></name><name><surname>Hauser</surname><given-names>MA</given-names></name><name><surname>Broomer</surname><given-names>BW</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name><name><surname>Ababio-Danso</surname><given-names>B</given-names></name><name><surname>Allingham</surname><given-names>RR</given-names></name></person-group><article-title>Prevalence of myocilin mutations in adults with primary open-angle glaucoma in Ghana, West Africa.</article-title><source>J Glaucoma</source><year>2002</year><volume>11</volume><fpage>416</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">12362081</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiggs</surname><given-names>JL</given-names></name><name><surname>Allingham</surname><given-names>RR</given-names></name><name><surname>Vollrath</surname><given-names>D</given-names></name><name><surname>Jones</surname><given-names>KH</given-names></name><name><surname>De La Paz</surname><given-names>M</given-names></name><name><surname>Kern</surname><given-names>J</given-names></name><name><surname>Patterson</surname><given-names>K</given-names></name><name><surname>Babb</surname><given-names>VL</given-names></name><name><surname>Del Bono</surname><given-names>EA</given-names></name><name><surname>Broomer</surname><given-names>BW</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name></person-group><article-title>Prevalence of mutations in TIGR/Myocilin in patients with adult and juvenile primary open-angle glaucoma.</article-title><source>Am J Hum Genet</source><year>1998</year><volume>63</volume><fpage>1549</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">9792882</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alward</surname><given-names>WL</given-names></name><name><surname>Fingert</surname><given-names>JH</given-names></name><name><surname>Coote</surname><given-names>MA</given-names></name><name><surname>Johnson</surname><given-names>AT</given-names></name><name><surname>Lerner</surname><given-names>SF</given-names></name><name><surname>Junqua</surname><given-names>D</given-names></name><name><surname>Durcan</surname><given-names>FJ</given-names></name><name><surname>McCartney</surname><given-names>PJ</given-names></name><name><surname>Mackey</surname><given-names>DA</given-names></name><name><surname>Sheffield</surname><given-names>VC</given-names></name><name><surname>Stone</surname><given-names>EM</given-names></name></person-group><article-title>Clinical features associated with mutations in the chromosome 1 open-angle glaucoma gene (GLC1A).</article-title><source>N Engl J Med</source><year>1998</year><volume>338</volume><fpage>1022</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9535666</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>EM</given-names></name><name><surname>Fingert</surname><given-names>JH</given-names></name><name><surname>Alward</surname><given-names>WL</given-names></name><name><surname>Nguyen</surname><given-names>TD</given-names></name><name><surname>Polansky</surname><given-names>JR</given-names></name><name><surname>Sunden</surname><given-names>SL</given-names></name><name><surname>Nishimura</surname><given-names>D</given-names></name><name><surname>Clark</surname><given-names>AF</given-names></name><name><surname>Nystuen</surname><given-names>A</given-names></name><name><surname>Nichols</surname><given-names>BE</given-names></name><name><surname>Mackey</surname><given-names>DA</given-names></name><name><surname>Ritch</surname><given-names>R</given-names></name><name><surname>Kalenak</surname><given-names>JW</given-names></name><name><surname>Craven</surname><given-names>ER</given-names></name><name><surname>Sheffield</surname><given-names>VC</given-names></name></person-group><article-title>Identification of a gene that causes primary open angle glaucoma.</article-title><source>Science</source><year>1997</year><volume>275</volume><fpage>668</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">9005853</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melki</surname><given-names>R</given-names></name><name><surname>Belmouden</surname><given-names>A</given-names></name><name><surname>Brezin</surname><given-names>A</given-names></name><name><surname>Garchon</surname><given-names>HJ</given-names></name></person-group><article-title>Myocilin analysis by DHPLC in French POAG patients: increased prevalence of Q368X mutation.</article-title><source>Hum Mutat</source><year>2003</year><volume>22</volume><fpage>179</fpage><pub-id pub-id-type="pmid">12872267</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escribano</surname><given-names>J</given-names></name><name><surname>Ortego</surname><given-names>J</given-names></name><name><surname>Coca-Prados</surname><given-names>M</given-names></name></person-group><article-title>Isolation and characterization of cell-specific cDNA clones from a subtractive library of the ocular ciliary body of a single normal human donor: transcription and synthesis of plasma proteins.</article-title><source>J Biochem</source><year>1995</year><volume>118</volume><fpage>921</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">8749308</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortego</surname><given-names>J</given-names></name><name><surname>Escribano</surname><given-names>J</given-names></name><name><surname>Coca-Prados</surname><given-names>M</given-names></name></person-group><article-title>Cloning and characterization of subtracted cDNAs from a human ciliary body library encoding TIGR, a protein involved in juvenile open angle glaucoma with homology to myosin and olfactomedin.</article-title><source>FEBS Lett</source><year>1997</year><volume>413</volume><fpage>349</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">9280311</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Jaroszewski</surname><given-names>J</given-names></name><name><surname>Ortego</surname><given-names>J</given-names></name><name><surname>Escribano</surname><given-names>J</given-names></name><name><surname>Coca-Prados</surname><given-names>M</given-names></name></person-group><article-title>Expression of the TIGR gene in the iris, ciliary body, and trabecular meshwork of the human eye.</article-title><source>Ophthalmic Genet</source><year>2000</year><volume>21</volume><fpage>155</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">11035548</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melki</surname><given-names>R</given-names></name><name><surname>Colomb</surname><given-names>E</given-names></name><name><surname>Lefort</surname><given-names>N</given-names></name><name><surname>Brezin</surname><given-names>AP</given-names></name><name><surname>Garchon</surname><given-names>HJ</given-names></name></person-group><article-title>CYP1B1 mutations in French patients with early-onset primary open-angle glaucoma.</article-title><source>J Med Genet</source><year>2004</year><volume>41</volume><fpage>647</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">15342693</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melki</surname><given-names>R</given-names></name><name><surname>Lefort</surname><given-names>N</given-names></name><name><surname>Brezin</surname><given-names>AP</given-names></name><name><surname>Garchon</surname><given-names>HJ</given-names></name></person-group><article-title>Association of a common coding polymorphism (N453S) of the cytochrome P450 1B1 (CYP1B1) gene with optic disc cupping and visual field alteration in French patients with primary open-angle glaucoma.</article-title><source>Mol Vis</source><year>2005</year><volume>11</volume><fpage>1012</fpage><lpage>7</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v11/a121/">http://www.molvis.org/molvis/v11/a121/</ext-link><pub-id pub-id-type="pmid">16319821</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acharya</surname><given-names>M</given-names></name><name><surname>Mookherjee</surname><given-names>S</given-names></name><name><surname>Bhattacharjee</surname><given-names>A</given-names></name><name><surname>Bandyopadhyay</surname><given-names>AK</given-names></name><name><surname>Daulat Thakur</surname><given-names>SK</given-names></name><name><surname>Bhaduri</surname><given-names>G</given-names></name><name><surname>Sen</surname><given-names>A</given-names></name><name><surname>Ray</surname><given-names>K</given-names></name></person-group><article-title>Primary role of CYP1B1 in Indian juvenile-onset POAG patients.</article-title><source>Mol Vis</source><year>2006</year><volume>12</volume><fpage>399</fpage><lpage>404</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v12/a46/">http://www.molvis.org/molvis/v12/a46/</ext-link><pub-id pub-id-type="pmid">16688110</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Garrido</surname><given-names>MP</given-names></name><name><surname>Sanchez-Sanchez</surname><given-names>F</given-names></name><name><surname>Lopez-Martinez</surname><given-names>F</given-names></name><name><surname>Aroca-Aguilar</surname><given-names>JD</given-names></name><name><surname>Blanco-Marchite</surname><given-names>C</given-names></name><name><surname>Coca-Prados</surname><given-names>M</given-names></name><name><surname>Escribano</surname><given-names>J</given-names></name></person-group><article-title>Heterozygous CYP1B1 gene mutations in Spanish patients with primary open-angle glaucoma.</article-title><source>Mol Vis</source><year>2006</year><volume>12</volume><fpage>748</fpage><lpage>55</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v12/a84/">http://www.molvis.org/molvis/v12/a84/</ext-link><pub-id pub-id-type="pmid">16862072</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rezaie</surname><given-names>T</given-names></name><name><surname>Child</surname><given-names>A</given-names></name><name><surname>Hitchings</surname><given-names>R</given-names></name><name><surname>Brice</surname><given-names>G</given-names></name><name><surname>Miller</surname><given-names>L</given-names></name><name><surname>Coca-Prados</surname><given-names>M</given-names></name><name><surname>Heon</surname><given-names>E</given-names></name><name><surname>Krupin</surname><given-names>T</given-names></name><name><surname>Ritch</surname><given-names>R</given-names></name><name><surname>Kreutzer</surname><given-names>D</given-names></name><name><surname>Crick</surname><given-names>RP</given-names></name><name><surname>Sarfarazi</surname><given-names>M</given-names></name></person-group><article-title>Adult-onset primary open-angle glaucoma caused by mutations in optineurin.</article-title><source>Science</source><year>2002</year><volume>295</volume><fpage>1077</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11834836</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="book">Hodapp E, Parrish RK, Anderson DR. Clinical decisions in glaucoma. St. Louis: Mosby; 1993.</mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caetano-Anolles</surname><given-names>G</given-names></name><name><surname>Gresshoff</surname><given-names>PM</given-names></name></person-group><article-title>Staining nucleic acids with silver: an alternative to radioisotopic and fluorescnece labeling.</article-title><source>Promega Notes</source><year>1994</year><volume>45</volume><fpage>13</fpage><lpage>20</lpage></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewontin</surname><given-names>RC</given-names></name></person-group><article-title>On measures of gametic disequilibrium.</article-title><source>Genetics</source><year>1988</year><volume>120</volume><fpage>849</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">3224810</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><article-title>Haploview: analysis and visualization of LD and haplotype maps.</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><fpage>263</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15297300</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Schaffner</surname><given-names>SF</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Moore</surname><given-names>JM</given-names></name><name><surname>Roy</surname><given-names>J</given-names></name><name><surname>Blumenstiel</surname><given-names>B</given-names></name><name><surname>Higgins</surname><given-names>J</given-names></name><name><surname>DeFelice</surname><given-names>M</given-names></name><name><surname>Lochner</surname><given-names>A</given-names></name><name><surname>Faggart</surname><given-names>M</given-names></name><name><surname>Liu-Cordero</surname><given-names>SN</given-names></name><name><surname>Rotimi</surname><given-names>C</given-names></name><name><surname>Adeyemo</surname><given-names>A</given-names></name><name><surname>Cooper</surname><given-names>R</given-names></name><name><surname>Ward</surname><given-names>R</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name></person-group><article-title>The structure of haplotype blocks in the human genome.</article-title><source>Science</source><year>2002</year><volume>296</volume><fpage>2225</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12029063</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Muse</surname><given-names>SV</given-names></name></person-group><article-title>PowerMarker: an integrated analysis environment for genetic marker analysis.</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><fpage>2128</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15705655</pub-id></mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aroca-Aguilar</surname><given-names>JD</given-names></name><name><surname>Sanchez-Sanchez</surname><given-names>F</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Coca-Prados</surname><given-names>M</given-names></name><name><surname>Escribano</surname><given-names>J</given-names></name></person-group><article-title>Myocilin mutations causing glaucoma inhibit the intracellular endoproteolytic cleavage of myocilin between amino acids Arg226 and Ile227.</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>21043</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">15795224</pub-id></mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>TD</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Huang</surname><given-names>WD</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Johnson</surname><given-names>D</given-names></name><name><surname>Polansky</surname><given-names>JR</given-names></name></person-group><article-title>Gene structure and properties of TIGR, an olfactomedin-related glycoprotein cloned from glucocorticoid-induced trabecular meshwork cells.</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><fpage>6341</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">9497363</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>YF</given-names></name><name><surname>Tam</surname><given-names>PO</given-names></name><name><surname>Baum</surname><given-names>L</given-names></name><name><surname>Lam</surname><given-names>DS</given-names></name><name><surname>Pang</surname><given-names>CC</given-names></name></person-group><article-title>TIGR/MYOC proximal promoter GT-repeat polymorphism is not associated with myopia.</article-title><source>Hum Mutat</source><year>2000</year><volume>16</volume><fpage>533</fpage><pub-id pub-id-type="pmid">11102993</pub-id></mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sjostrand</surname><given-names>A</given-names></name><name><surname>Tomic</surname><given-names>L</given-names></name><name><surname>Larsson</surname><given-names>LI</given-names></name><name><surname>Wadelius</surname><given-names>C</given-names></name></person-group><article-title>No evidence of association between GT/CA-repeat polymorphism in the GLC1A gene promoter and primary open-angle or exfoliation glaucoma.</article-title><source>Acta Ophthalmol Scand</source><year>2002</year><volume>80</volume><fpage>384</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12190780</pub-id></mixed-citation></ref><ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fingert</surname><given-names>JH</given-names></name><name><surname>Heon</surname><given-names>E</given-names></name><name><surname>Liebmann</surname><given-names>JM</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Craig</surname><given-names>JE</given-names></name><name><surname>Rait</surname><given-names>J</given-names></name><name><surname>Kawase</surname><given-names>K</given-names></name><name><surname>Hoh</surname><given-names>ST</given-names></name><name><surname>Buys</surname><given-names>YM</given-names></name><name><surname>Dickinson</surname><given-names>J</given-names></name><name><surname>Hockey</surname><given-names>RR</given-names></name><name><surname>Williams-Lyn</surname><given-names>D</given-names></name><name><surname>Trope</surname><given-names>G</given-names></name><name><surname>Kitazawa</surname><given-names>Y</given-names></name><name><surname>Ritch</surname><given-names>R</given-names></name><name><surname>Mackey</surname><given-names>DA</given-names></name><name><surname>Alward</surname><given-names>WL</given-names></name><name><surname>Sheffield</surname><given-names>VC</given-names></name><name><surname>Stone</surname><given-names>EM</given-names></name></person-group><article-title>Analysis of myocilin mutations in 1703 glaucoma patients from five different populations.</article-title><source>Hum Mol Genet</source><year>1999</year><volume>8</volume><fpage>899</fpage><lpage>905</lpage><pub-id pub-id-type="pmid">10196380</pub-id></mixed-citation></ref><ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angius</surname><given-names>A</given-names></name><name><surname>Spinelli</surname><given-names>P</given-names></name><name><surname>Ghilotti</surname><given-names>G</given-names></name><name><surname>Casu</surname><given-names>G</given-names></name><name><surname>Sole</surname><given-names>G</given-names></name><name><surname>Loi</surname><given-names>A</given-names></name><name><surname>Totaro</surname><given-names>A</given-names></name><name><surname>Zelante</surname><given-names>L</given-names></name><name><surname>Gasparini</surname><given-names>P</given-names></name><name><surname>Orzalesi</surname><given-names>N</given-names></name><name><surname>Pirastu</surname><given-names>M</given-names></name><name><surname>Bonomi</surname><given-names>L</given-names></name></person-group><article-title>Myocilin Gln368stop mutation and advanced age as risk factors for late-onset primary open-angle glaucoma.</article-title><source>Arch Ophthalmol</source><year>2000</year><volume>118</volume><fpage>674</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10815160</pub-id></mixed-citation></ref><ref id="r31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>MF</given-names></name><name><surname>Belmouden</surname><given-names>A</given-names></name><name><surname>Binisti</surname><given-names>P</given-names></name><name><surname>Brezin</surname><given-names>AP</given-names></name><name><surname>Valtot</surname><given-names>F</given-names></name><name><surname>Bechetoille</surname><given-names>A</given-names></name><name><surname>Dascotte</surname><given-names>JC</given-names></name><name><surname>Copin</surname><given-names>B</given-names></name><name><surname>Gomez</surname><given-names>L</given-names></name><name><surname>Chaventre</surname><given-names>A</given-names></name><name><surname>Bach</surname><given-names>JF</given-names></name><name><surname>Garchon</surname><given-names>HJ</given-names></name></person-group><article-title>Recurrent mutations in a single exon encoding the evolutionarily conserved olfactomedin-homology domain of TIGR in familial open-angle glaucoma.</article-title><source>Hum Mol Genet</source><year>1997</year><volume>6</volume><fpage>2091</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9328473</pub-id></mixed-citation></ref><ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caballero</surname><given-names>M</given-names></name><name><surname>Rowlette</surname><given-names>LL</given-names></name><name><surname>Borras</surname><given-names>T</given-names></name></person-group><article-title>Altered secretion of a TIGR/MYOC mutant lacking the olfactomedin domain.</article-title><source>Biochim Biophys Acta</source><year>2000</year><volume>1502</volume><fpage>447</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">11068187</pub-id></mixed-citation></ref><ref id="r33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caballero</surname><given-names>M</given-names></name><name><surname>Borras</surname><given-names>T</given-names></name></person-group><article-title>Inefficient processing of an olfactomedin-deficient myocilin mutant: potential physiological relevance to glaucoma.</article-title><source>Biochem Biophys Res Commun</source><year>2001</year><volume>282</volume><fpage>662</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">11401512</pub-id></mixed-citation></ref><ref id="r34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname><given-names>N</given-names></name><name><surname>Andrews</surname><given-names>M</given-names></name><name><surname>Shepard</surname><given-names>AR</given-names></name><name><surname>Nishimura</surname><given-names>D</given-names></name><name><surname>Searby</surname><given-names>C</given-names></name><name><surname>Fingert</surname><given-names>JH</given-names></name><name><surname>Hageman</surname><given-names>G</given-names></name><name><surname>Mullins</surname><given-names>R</given-names></name><name><surname>Davidson</surname><given-names>BL</given-names></name><name><surname>Kwon</surname><given-names>YH</given-names></name><name><surname>Alward</surname><given-names>WL</given-names></name><name><surname>Stone</surname><given-names>EM</given-names></name><name><surname>Clark</surname><given-names>AF</given-names></name><name><surname>Sheffield</surname><given-names>VC</given-names></name></person-group><article-title>Non-secretion of mutant proteins of the glaucoma gene myocilin in cultured trabecular meshwork cells and in aqueous humor.</article-title><source>Hum Mol Genet</source><year>2001</year><volume>10</volume><fpage>117</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">11152659</pub-id></mixed-citation></ref><ref id="r35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Vollrath</surname><given-names>D</given-names></name></person-group><article-title>Reversal of mutant myocilin non-secretion and cell killing: implications for glaucoma.</article-title><source>Hum Mol Genet</source><year>2004</year><volume>13</volume><fpage>1193</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">15069026</pub-id></mixed-citation></ref><ref id="r36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sohn</surname><given-names>S</given-names></name><name><surname>Hur</surname><given-names>W</given-names></name><name><surname>Joe</surname><given-names>MK</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>ZW</given-names></name><name><surname>Ha</surname><given-names>KS</given-names></name><name><surname>Kee</surname><given-names>C</given-names></name></person-group><article-title>Expression of wild-type and truncated myocilins in trabecular meshwork cells: their subcellular localizations and cytotoxicities.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2002</year><volume>43</volume><fpage>3680</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">12454036</pub-id></mixed-citation></ref><ref id="r37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>BJ</given-names></name><name><surname>Wang</surname><given-names>DY</given-names></name><name><surname>Fan</surname><given-names>DS</given-names></name><name><surname>Tam</surname><given-names>PO</given-names></name><name><surname>Lam</surname><given-names>DS</given-names></name><name><surname>Tham</surname><given-names>CC</given-names></name><name><surname>Lam</surname><given-names>CY</given-names></name><name><surname>Lau</surname><given-names>TC</given-names></name><name><surname>Pang</surname><given-names>CP</given-names></name></person-group><article-title>SNPs and interaction analyses of myocilin, optineurin, and apolipoprotein E in primary open angle glaucoma patients.</article-title><source>Mol Vis</source><year>2005</year><volume>11</volume><fpage>625</fpage><lpage>31</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v11/a74/">http://www.molvis.org/molvis/v11/a74/</ext-link><pub-id pub-id-type="pmid">16148883</pub-id></mixed-citation></ref><ref id="r38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funayama</surname><given-names>T</given-names></name><name><surname>Ishikawa</surname><given-names>K</given-names></name><name><surname>Ohtake</surname><given-names>Y</given-names></name><name><surname>Tanino</surname><given-names>T</given-names></name><name><surname>Kurosaka</surname><given-names>D</given-names></name><name><surname>Kimura</surname><given-names>I</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Ideta</surname><given-names>H</given-names></name><name><surname>Nakamoto</surname><given-names>K</given-names></name><name><surname>Yasuda</surname><given-names>N</given-names></name><name><surname>Fujimaki</surname><given-names>T</given-names></name><name><surname>Murakami</surname><given-names>A</given-names></name><name><surname>Asaoka</surname><given-names>R</given-names></name><name><surname>Hotta</surname><given-names>Y</given-names></name><name><surname>Tanihara</surname><given-names>H</given-names></name><name><surname>Kanamoto</surname><given-names>T</given-names></name><name><surname>Mishima</surname><given-names>H</given-names></name><name><surname>Fukuchi</surname><given-names>T</given-names></name><name><surname>Abe</surname><given-names>H</given-names></name><name><surname>Iwata</surname><given-names>T</given-names></name><name><surname>Shimada</surname><given-names>N</given-names></name><name><surname>Kudoh</surname><given-names>J</given-names></name><name><surname>Shimizu</surname><given-names>N</given-names></name><name><surname>Mashima</surname><given-names>Y</given-names></name></person-group><article-title>Variants in optineurin gene and their association with tumor necrosis factor-alpha polymorphisms in Japanese patients with glaucoma.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2004</year><volume>45</volume><fpage>4359</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">15557444</pub-id></mixed-citation></ref><ref id="r39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sripriya</surname><given-names>S</given-names></name><name><surname>Nirmaladevi</surname><given-names>J</given-names></name><name><surname>George</surname><given-names>R</given-names></name><name><surname>Hemamalini</surname><given-names>A</given-names></name><name><surname>Baskaran</surname><given-names>M</given-names></name><name><surname>Prema</surname><given-names>R</given-names></name><name><surname>Ve Ramesh</surname><given-names>S</given-names></name><name><surname>Karthiyayini</surname><given-names>T</given-names></name><name><surname>Amali</surname><given-names>J</given-names></name><name><surname>Job</surname><given-names>S</given-names></name><name><surname>Vijaya</surname><given-names>L</given-names></name><name><surname>Kumaramanickavel</surname><given-names>G</given-names></name></person-group><article-title>OPTN gene: profile of patients with glaucoma from India.</article-title><source>Mol Vis</source><year>2006</year><volume>12</volume><fpage>816</fpage><lpage>20</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v12/a92/">http://www.molvis.org/molvis/v12/a92/</ext-link><pub-id pub-id-type="pmid">16885925</pub-id></mixed-citation></ref><ref id="r40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alward</surname><given-names>WL</given-names></name><name><surname>Kwon</surname><given-names>YH</given-names></name><name><surname>Kawase</surname><given-names>K</given-names></name><name><surname>Craig</surname><given-names>JE</given-names></name><name><surname>Hayreh</surname><given-names>SS</given-names></name><name><surname>Johnson</surname><given-names>AT</given-names></name><name><surname>Khanna</surname><given-names>CL</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Mackey</surname><given-names>DA</given-names></name><name><surname>Roos</surname><given-names>BR</given-names></name><name><surname>Affatigato</surname><given-names>LM</given-names></name><name><surname>Sheffield</surname><given-names>VC</given-names></name><name><surname>Stone</surname><given-names>EM</given-names></name></person-group><article-title>Evaluation of optineurin sequence variations in 1,048 patients with open-angle glaucoma.</article-title><source>Am J Ophthalmol</source><year>2003</year><volume>136</volume><fpage>904</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">14597044</pub-id></mixed-citation></ref><ref id="r41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graul</surname><given-names>TA</given-names></name><name><surname>Kwon</surname><given-names>YH</given-names></name><name><surname>Zimmerman</surname><given-names>MB</given-names></name><name><surname>Kim</surname><given-names>CS</given-names></name><name><surname>Sheffield</surname><given-names>VC</given-names></name><name><surname>Stone</surname><given-names>EM</given-names></name><name><surname>Alward</surname><given-names>WL</given-names></name></person-group><article-title>A case-control comparison of the clinical characteristics of glaucoma and ocular hypertensive patients with and without the myocilin Gln368Stop mutation.</article-title><source>Am J Ophthalmol</source><year>2002</year><volume>134</volume><fpage>884</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">12470758</pub-id></mixed-citation></ref><ref id="r42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allingham</surname><given-names>RR</given-names></name><name><surname>Wiggs</surname><given-names>JL</given-names></name><name><surname>De La Paz</surname><given-names>MA</given-names></name><name><surname>Vollrath</surname><given-names>D</given-names></name><name><surname>Tallett</surname><given-names>DA</given-names></name><name><surname>Broomer</surname><given-names>B</given-names></name><name><surname>Jones</surname><given-names>KH</given-names></name><name><surname>Del Bono</surname><given-names>EA</given-names></name><name><surname>Kern</surname><given-names>J</given-names></name><name><surname>Patterson</surname><given-names>K</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name></person-group><article-title>Gln368STOP myocilin mutation in families with late-onset primary open-angle glaucoma.</article-title><source>Invest Ophthalmol Vis Sci</source><year>1998</year><volume>39</volume><fpage>2288</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">9804137</pub-id></mixed-citation></ref><ref id="r43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>AL</given-names></name><name><surname>Billingsley</surname><given-names>G</given-names></name><name><surname>Buys</surname><given-names>Y</given-names></name><name><surname>Levin</surname><given-names>AV</given-names></name><name><surname>Priston</surname><given-names>M</given-names></name><name><surname>Trope</surname><given-names>G</given-names></name><name><surname>Williams-Lyn</surname><given-names>D</given-names></name><name><surname>Heon</surname><given-names>E</given-names></name></person-group><article-title>Digenic inheritance of early-onset glaucoma: CYP1B1, a potential modifier gene.</article-title><source>Am J Hum Genet</source><year>2002</year><volume>70</volume><fpage>448</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">11774072</pub-id></mixed-citation></ref><ref id="r44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faucher</surname><given-names>M</given-names></name><name><surname>Anctil</surname><given-names>JL</given-names></name><name><surname>Rodrigue</surname><given-names>MA</given-names></name><name><surname>Duchesne</surname><given-names>A</given-names></name><name><surname>Bergeron</surname><given-names>D</given-names></name><name><surname>Blondeau</surname><given-names>P</given-names></name><name><surname>Cote</surname><given-names>G</given-names></name><name><surname>Dubois</surname><given-names>S</given-names></name><name><surname>Bergeron</surname><given-names>J</given-names></name><name><surname>Arseneault</surname><given-names>R</given-names></name><name><surname>Morissette</surname><given-names>J</given-names></name><name><surname>Raymond</surname><given-names>V</given-names></name><collab>Quebec Glaucoma Network.</collab></person-group><article-title>Founder TIGR/myocilin mutations for glaucoma in the Quebec population.</article-title><source>Hum Mol Genet</source><year>2002</year><volume>11</volume><fpage>2077</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">12189160</pub-id></mixed-citation></ref><ref id="r45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aung</surname><given-names>T</given-names></name><name><surname>Yong</surname><given-names>VH</given-names></name><name><surname>Chew</surname><given-names>PT</given-names></name><name><surname>Seah</surname><given-names>SK</given-names></name><name><surname>Gazzard</surname><given-names>G</given-names></name><name><surname>Foster</surname><given-names>PJ</given-names></name><name><surname>Vithana</surname><given-names>EN</given-names></name></person-group><article-title>Molecular analysis of the myocilin gene in Chinese subjects with chronic primary-angle closure glaucoma.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2005</year><volume>46</volume><fpage>1303</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15790895</pub-id></mixed-citation></ref><ref id="r46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vazquez</surname><given-names>CM</given-names></name><name><surname>Herrero</surname><given-names>OM</given-names></name><name><surname>Bastus</surname><given-names>BM</given-names></name><name><surname>Perez</surname><given-names>VD</given-names></name></person-group><article-title>Mutations in the third exon of the MYOC gene in spanish patients with primary open angle glaucoma.</article-title><source>Ophthalmic Genet</source><year>2000</year><volume>21</volume><fpage>109</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">10916185</pub-id></mixed-citation></ref><ref id="r47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saura</surname><given-names>M</given-names></name><name><surname>Cabana</surname><given-names>M</given-names></name><name><surname>Ayuso</surname><given-names>C</given-names></name><name><surname>Valverde</surname><given-names>D</given-names></name></person-group><article-title>Mutations including the promoter region of myocilin/TIGR gene.</article-title><source>Eur J Hum Genet</source><year>2005</year><volume>13</volume><fpage>384</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15483649</pub-id></mixed-citation></ref><ref id="r48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gould</surname><given-names>DB</given-names></name><name><surname>Smith</surname><given-names>RS</given-names></name><name><surname>John</surname><given-names>SW</given-names></name></person-group><article-title>Anterior segment development relevant to glaucoma.</article-title><source>Int J Dev Biol</source><year>2004</year><volume>48</volume><fpage>1015</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">15558492</pub-id></mixed-citation></ref><ref id="r49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gould</surname><given-names>DB</given-names></name><name><surname>Reedy</surname><given-names>M</given-names></name><name><surname>Wilson</surname><given-names>LA</given-names></name><name><surname>Smith</surname><given-names>RS</given-names></name><name><surname>Johnson</surname><given-names>RL</given-names></name><name><surname>John</surname><given-names>SW</given-names></name></person-group><article-title>Mutant myocilin nonsecretion in vivo is not sufficient to cause glaucoma.</article-title><source>Mol Cell Biol</source><year>2006</year><volume>26</volume><fpage>8427</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">16954374</pub-id></mixed-citation></ref><ref id="r50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alward</surname><given-names>WL</given-names></name><name><surname>Kwon</surname><given-names>YH</given-names></name><name><surname>Khanna</surname><given-names>CL</given-names></name><name><surname>Johnson</surname><given-names>AT</given-names></name><name><surname>Hayreh</surname><given-names>SS</given-names></name><name><surname>Zimmerman</surname><given-names>MB</given-names></name><name><surname>Narkiewicz</surname><given-names>J</given-names></name><name><surname>Andorf</surname><given-names>JL</given-names></name><name><surname>Moore</surname><given-names>PA</given-names></name><name><surname>Fingert</surname><given-names>JH</given-names></name><name><surname>Sheffield</surname><given-names>VC</given-names></name><name><surname>Stone</surname><given-names>EM</given-names></name></person-group><article-title>Variations in the myocilin gene in patients with open-angle glaucoma.</article-title><source>Arch Ophthalmol</source><year>2002</year><volume>120</volume><fpage>1189</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">12215093</pub-id></mixed-citation></ref><ref id="r51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colomb</surname><given-names>E</given-names></name><name><surname>Nguyen</surname><given-names>TD</given-names></name><name><surname>Bechetoille</surname><given-names>A</given-names></name><name><surname>Dascotte</surname><given-names>JC</given-names></name><name><surname>Valtot</surname><given-names>F</given-names></name><name><surname>Brezin</surname><given-names>AP</given-names></name><name><surname>Berkani</surname><given-names>M</given-names></name><name><surname>Copin</surname><given-names>B</given-names></name><name><surname>Gomez</surname><given-names>L</given-names></name><name><surname>Polansky</surname><given-names>JR</given-names></name><name><surname>Garchon</surname><given-names>HJ</given-names></name></person-group><article-title>Association of a single nucleotide polymorphism in the TIGR/MYOCILIN gene promoter with the severity of primary open-angle glaucoma.</article-title><source>Clin Genet</source><year>2001</year><volume>60</volume><fpage>220</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">11595024</pub-id></mixed-citation></ref><ref id="r52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozgul</surname><given-names>RK</given-names></name><name><surname>Bozkurt</surname><given-names>B</given-names></name><name><surname>Orcan</surname><given-names>S</given-names></name><name><surname>Bulur</surname><given-names>B</given-names></name><name><surname>Bagiyeva</surname><given-names>S</given-names></name><name><surname>Irkec</surname><given-names>M</given-names></name><name><surname>Ogus</surname><given-names>A</given-names></name></person-group><article-title>Myocilin mt1 promoter polymorphism in Turkish patients with primary open angle glaucoma.</article-title><source>Mol Vis</source><year>2005</year><volume>11</volume><fpage>916</fpage><lpage>21</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v11/a109/">http://www.molvis.org/molvis/v11/a109/</ext-link><pub-id pub-id-type="pmid">16280977</pub-id></mixed-citation></ref><ref id="r53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>BJ</given-names></name><name><surname>Leung</surname><given-names>YF</given-names></name><name><surname>Pang</surname><given-names>CP</given-names></name><name><surname>Fan</surname><given-names>DS</given-names></name><name><surname>Wang</surname><given-names>DY</given-names></name><name><surname>Tong</surname><given-names>WC</given-names></name><name><surname>Tam</surname><given-names>PO</given-names></name><name><surname>Chua</surname><given-names>JK</given-names></name><name><surname>Lau</surname><given-names>TC</given-names></name><name><surname>Lam</surname><given-names>DS</given-names></name></person-group><article-title>Polymorphisms in the myocilin promoter unrelated to the risk and severity of primary open-angle glaucoma.</article-title><source>J Glaucoma</source><year>2004</year><volume>13</volume><fpage>377</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">15354075</pub-id></mixed-citation></ref><ref id="r54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>DS</given-names></name><name><surname>Leung</surname><given-names>YF</given-names></name><name><surname>Chua</surname><given-names>JK</given-names></name><name><surname>Baum</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>DS</given-names></name><name><surname>Choy</surname><given-names>KW</given-names></name><name><surname>Pang</surname><given-names>CP</given-names></name></person-group><article-title>Truncations in the TIGR gene in individuals with and without primary open-angle glaucoma.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2000</year><volume>41</volume><fpage>1386</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">10798654</pub-id></mixed-citation></ref><ref id="r55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mabuchi</surname><given-names>F</given-names></name><name><surname>Yamagata</surname><given-names>Z</given-names></name><name><surname>Kashiwagi</surname><given-names>K</given-names></name><name><surname>Tang</surname><given-names>S</given-names></name><name><surname>Iijima</surname><given-names>H</given-names></name><name><surname>Tsukahara</surname><given-names>S</given-names></name></person-group><article-title>Analysis of myocilin gene mutations in Japanese patients with normal tension glaucoma and primary open-angle glaucoma.</article-title><source>Clin Genet</source><year>2001</year><volume>59</volume><fpage>263</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11298682</pub-id></mixed-citation></ref><ref id="r56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>DY</given-names></name><name><surname>Fan</surname><given-names>BJ</given-names></name><name><surname>Canlas</surname><given-names>O</given-names></name><name><surname>Tam</surname><given-names>PO</given-names></name><name><surname>Ritch</surname><given-names>R</given-names></name><name><surname>Lam</surname><given-names>DS</given-names></name><name><surname>Fan</surname><given-names>DS</given-names></name><name><surname>Pang</surname><given-names>CP</given-names></name></person-group><article-title>Absence of myocilin and optineurin mutations in a large Philippine family with juvenile onset primary open angle glaucoma.</article-title><source>Mol Vis</source><year>2004</year><volume>10</volume><fpage>851</fpage><lpage>6</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v10/a102/">http://www.molvis.org/molvis/v10/a102/</ext-link><pub-id pub-id-type="pmid">15547491</pub-id></mixed-citation></ref><ref id="r57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>CP</given-names></name><name><surname>Leung</surname><given-names>YF</given-names></name><name><surname>Fan</surname><given-names>B</given-names></name><name><surname>Baum</surname><given-names>L</given-names></name><name><surname>Tong</surname><given-names>WC</given-names></name><name><surname>Lee</surname><given-names>WS</given-names></name><name><surname>Chua</surname><given-names>JK</given-names></name><name><surname>Fan</surname><given-names>DS</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Lam</surname><given-names>DS</given-names></name></person-group><article-title>TIGR/MYOC gene sequence alterations in individuals with and without primary open-angle glaucoma.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2002</year><volume>43</volume><fpage>3231</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">12356829</pub-id></mixed-citation></ref><ref id="r58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukhopadhyay</surname><given-names>A</given-names></name><name><surname>Acharya</surname><given-names>M</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ray</surname><given-names>J</given-names></name><name><surname>Choudhury</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Ray</surname><given-names>K</given-names></name></person-group><article-title>Mutations in MYOC gene of Indian primary open angle glaucoma patients.</article-title><source>Mol Vis</source><year>2002</year><volume>8</volume><fpage>442</fpage><lpage>8</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v8/a53/">http://www.molvis.org/molvis/v8/a53/</ext-link><pub-id pub-id-type="pmid">12447164</pub-id></mixed-citation></ref><ref id="r59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>YF</given-names></name><name><surname>Fan</surname><given-names>BJ</given-names></name><name><surname>Lam</surname><given-names>DS</given-names></name><name><surname>Lee</surname><given-names>WS</given-names></name><name><surname>Tam</surname><given-names>PO</given-names></name><name><surname>Chua</surname><given-names>JK</given-names></name><name><surname>Tham</surname><given-names>CC</given-names></name><name><surname>Lai</surname><given-names>JS</given-names></name><name><surname>Fan</surname><given-names>DS</given-names></name><name><surname>Pang</surname><given-names>CP</given-names></name></person-group><article-title>Different optineurin mutation pattern in primary open-angle glaucoma.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2003</year><volume>44</volume><fpage>3880</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">12939304</pub-id></mixed-citation></ref><ref id="r60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiggs</surname><given-names>JL</given-names></name><name><surname>Auguste</surname><given-names>J</given-names></name><name><surname>Allingham</surname><given-names>RR</given-names></name><name><surname>Flor</surname><given-names>JD</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name><name><surname>Rogers</surname><given-names>K</given-names></name><name><surname>LaRocque</surname><given-names>KR</given-names></name><name><surname>Graham</surname><given-names>FL</given-names></name><name><surname>Broomer</surname><given-names>B</given-names></name><name><surname>Del Bono</surname><given-names>E</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Hauser</surname><given-names>M</given-names></name></person-group><article-title>Lack of association of mutations in optineurin with disease in patients with adult-onset primary open-angle glaucoma.</article-title><source>Arch Ophthalmol</source><year>2003</year><volume>121</volume><fpage>1181</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">12912697</pub-id></mixed-citation></ref><ref id="r61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melki</surname><given-names>R</given-names></name><name><surname>Belmouden</surname><given-names>A</given-names></name><name><surname>Akhayat</surname><given-names>O</given-names></name><name><surname>Brezin</surname><given-names>A</given-names></name><name><surname>Garchon</surname><given-names>HJ</given-names></name></person-group><article-title>The M98K variant of the OPTINEURIN (OPTN) gene modifies initial intraocular pressure in patients with primary open angle glaucoma.</article-title><source>J Med Genet</source><year>2003</year><volume>40</volume><fpage>842</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">14627677</pub-id></mixed-citation></ref><ref id="r62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ariani</surname><given-names>F</given-names></name><name><surname>Longo</surname><given-names>I</given-names></name><name><surname>Frezzotti</surname><given-names>P</given-names></name><name><surname>Pescucci</surname><given-names>C</given-names></name><name><surname>Mari</surname><given-names>F</given-names></name><name><surname>Caporossi</surname><given-names>A</given-names></name><name><surname>Frezzotti</surname><given-names>R</given-names></name><name><surname>Renieri</surname><given-names>A</given-names></name></person-group><article-title>Optineurin gene is not involved in the common high-tension form of primary open-angle glaucoma.</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2006</year><volume>244</volume><fpage>1077</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">16440206</pub-id></mixed-citation></ref><ref id="r63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirstein</surname><given-names>L</given-names></name><name><surname>Cvekl</surname><given-names>A</given-names></name><name><surname>Chauhan</surname><given-names>BK</given-names></name><name><surname>Tamm</surname><given-names>ER</given-names></name></person-group><article-title>Regulation of human myocilin/TIGR gene transcription in trabecular meshwork cells and astrocytes: role of upstream stimulatory factor.</article-title><source>Genes Cells</source><year>2000</year><volume>5</volume><fpage>661</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">10947851</pub-id></mixed-citation></ref></ref-list></back></article>